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1.  Introduction 
 
1.1 Diabetes mellitus 
 
Diabetes mellitus (DM) refers to a group of metabolic disorders with the common 
phenotype of hyperglycemia. Complex interaction of genetic and environmental factors 
results in distinct types of DM mainly by reduced insulin secretion, decreased glucose 
utilization, and increased glucose production (Beck-Nielsen 2002). Depending on the 
etiology, DM is classified into different types. Two major types of DM, type 1 and type 2, 
are discussed below. Maturity onset diabetes of the young (MODY) is a genetic autosomal 
dominant disorder which occurs usually in people younger than 25 years and 
characterized by insulin secretion impairment. Gestational diabetes mellitus (GDM) may 
develop during pregnancy, in which metabolic changes of late pregnancy resulted in 
insulin resistance, subsequently the increased insulin requirement may lead to impaired 
glucose tolerance (IGT). Mutation in insulin receptor, destruction of pancreatic islet due to 
pancreatic exocrine disease, antagonizing of insulin action by hormones, and viral 
infection of islets (fulminant diabetes) are the etiologies for some rare subtypes of DM.   
  
1.1.a Type 1 diabetes mellitus 
Type 1 diabetes is a chronic autoimmune disease in which the pancreatic insulin-
producing β-cells are selectively destroyed by the immune system (Eisenbarth 1986). This 
type of diabetes is characterized by the progressive infiltration of pancreatic β-cells by 
CD4+ and CD8+ T-cells, as well as macrophages, which are critical mediators of 
inflammation by the secretion of cytokines, like IL-1β and TNFα, and reactive oxygen 
species (ROS)(Miller, Appel et al. 1988; Hutchings, Rosen et al. 1990; El-Sheikh, Suarez-
Pinzon et al. 1999; Phillips, Parish et al. 2009). This infiltration can result in insulitis and 
impaired insulin production, and subsequently in overt disease due to the destruction of 
the β-cells and absolute insulin deficiency. B-cells and the other cell types like NK (natural 
killer) cells and NKT (natural killer T) cells may be involved in part or a cross-talk between 
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Figure 1. 1 β-cell killing in type 1 diabetes. CD8
+
 T-cells through recognition of the presented 
antigens (MHC) may be involved in direct cytotoxicity by production of lytic granules. Cytokines 
may induce apoptosis through an inflammatory process. T-effector cells may leads to apoptosis by 
recruiting death domain signaling, such as FAS/FASL signal. ROS derived from activated 
macrophages may have direct toxic effects on β-cells (Bending, Zaccone et al. 2012).  
 
1.1.b Type 2 diabetes mellitus 
 Type 2 diabetes becomes clinically apparent when the endocrine pancreas fails to 
secrete sufficient insulin to overcome the high metabolic demand which has been raised 
due to insulin resistance followed by hyperglycemia (Lingohr, Buettner et al. 2002; Donath 
and Halban 2004). This failure of endocrine pancreas may be because of the acquired β-
cell secretory dysfunction (Leahy 1990; Kahn 2001; Kahn, Hull et al. 2006) and/or β-cell 
mass decline (Donath and Halban 2004; Weir and Bonner-Weir 2004).  
 Insulin resistance refers to the diminished ability of the cells (e.x. adipocytes, 
myocytes, and hepatocytes) in responding to the action of insulin. In a non-diabetic 
hyperglycemic patient, β-cells compensate the metabolic demand through morphological 
changes like hyperplasia and by producing and secretion of more insulin, termed 
hyperinsulinemia. Short term hyperinsulinemia might be tolerated, but chronic 
hyperinsulinemia might be detrimental and involved in β-cell failure (White 2003) and 
insulin insensitivity in adipocytes through strong activation of p42/44 MAPK pathway 
(Engelman, Berg et al. 2000). Obesity as a risk factor for the development of type 2 
diabetes contributes to insulin resistance, since adipocytes secrete adipokines, the 
proteins may influence the insulin sensitivity (Kahn and Flier 2000).  
 Nearly 60 years ago, the importance of β-cell loss in pathogenesis of type 2 
diabetes was hypothesized (Maclean and Ogilvie 1955). This hypothesis was withdrawn 
and the insulin resistance was for many years the only acceptable explanation for type 2 
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diabetes. The role of β-cell decline in pathogenesis of type 2 diabetes has strongly 
returned to the field of debates few years ago (Donath and Halban 2004). Beside the 
genetic background, several environmental factors might be involved in β-cell failure and 
decline, such as glucose, free fatty acids (FFA), and adipose tissue derived factors 
adipokines. Although glucose is an essential fuel for β-cells’ survival and metabolic activity 
(Hugl, White et al. 1998; Srinivasan, Bernal-Mizrachi et al. 2002) hyperglycemia has 
severe deleterious effects on β-cells (Sako and Grill 1990; Leahy, Bumbalo et al. 1994) 
which finally leads to diminished insulin secretion and stores, termed glucotoxicity 
(Rossetti, Giaccari et al. 1990; Kaiser, Corcos et al. 1991; Eizirik, Korbutt et al. 1992; 
Leahy, Bonner-Weir et al. 1992; Ling, Kiekens et al. 1996; Marshak, Leibowitz et al. 
1999). High glucose concentration participates in β-cells dysfunction by different 
mechanisms, such as generation of reactive oxygen species (Kaneto, Kawamori et al. 
2004; Robertson, Harmon et al. 2004), formation of advanced glycation end products 
(Tajiri, Moller et al. 1997), activation of mitogen-activated protein kinase (MAPK) family 
(Briaud, Lingohr et al. 2003; Khoo, Gibson et al. 2004; Maedler, Storling et al. 2004), 
impairment of insulin gene transcription and proinsulin biosynthesis (Robertson, Zhang et 
al. 1992; Robertson, Olson et al. 1994), reduction in the binding activity of pancreatic 
duodenal homebox 1 (PDX-1) (Marshak, Leibowitz et al. 1999), and triggering the 
endoplasmic reticulum (ER) stress (Wang, Kouri et al. 2005). 
 Increased plasma level of FFA which have been reported in the state of insulin 
resistance (Walker, O'Dea et al. 1996), is considered as a toxic element for β-cells, 
referring to the concept of lipotoxicity (Unger 1995; McGarry and Dobbins 1999; Maedler, 
Spinas et al. 2001). The mechanism underlying the lipotoxicity in β-cells might include the 
ER stress (Oyadomari, Araki et al. 2002; Karaskov, Scott et al. 2006). Fig 1.2 depicts 
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Figure 1. 2 Factors affecting the survival and function of β-cells. In diabetic condition, 
increased level of glucose, pro-inflammatory cytokines, adipokines and toxic IAPP (Islet Amyloid 
Polypeptide) oligomers activate downstream pathways leading to apoptosis and impaired function. 
Interleukin-1β receptor antagonist (IL-1βRa), inhibitors of c-Jun N-terminal kinase (JNKi) and the 
inhibitors of nuclear factor κB (NFκB) activation (peroxisome proliferator-activated receptor-γ 
[PPARγ] agonists, cyclooxygenase [COX] inhibitors) might preserve a functional β-cell mass 
(Maedler 2008).  
 
 
1.2 Pro-inflammtory cytokines and diabetes mellitus 
 
1.2 a IL-1β 
 For the first time in 1972, interleukin-1 (IL-1) was introduced as a lymphocyte-
activating factor (Gery, Gershon et al. 1972). Later in 1985, IL-1 was classified into two 
distinct prototypes, IL-1α and IL-1β, which are synthesized in monocytes (March, Mosley 
et al. 1985). The IL-1 receptor family has been introduced in two type, IL-1RI and IL-1RII, 
which comprising at least 9 members, IL-1R1 to 1R9 (Sims 2002). IL-1β exerts its 
inflammatory effects via binding to IL-1RI while IL-1RII appears to act as a decoy 
molecule, particularly for IL-1β (Mantovani, Locati et al. 2001). The binding of IL-1 to IL-
1RI recruits the interleukin-1 receptor accessory protein (IL-1RAcP), which is known as IL-
1R3, to the ligand/receptor complex and subsequently induces signal transduction 
(Wesche, Korherr et al. 1997). Interleukin-1 receptor antagonist (IL-1Ra) is another 
member of IL-1 family which acts as a natural antagonist for IL-1R via binding to the 
receptor without inducing signal transduction (Carter, Deibel et al. 1990; Eisenberg, Evans 
et al. 1990; Dinarello 1991; Dripps, Brandhuber et al. 1991; Granowitz, Clark et al. 1991).   
 The role of IL-1β in Type 1 and Type 2 diabetes has been demonstrated (Eizirik 
and Mandrup-Poulsen 2001; Guest, Park et al. 2008; Feve and Bastard 2009). IL-1β 
alone or in combination with interferon (IFN) γ and/or TNFα induces the pancreatic islet 
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apoptotic cell death and function impairment (Eizirik and Mandrup-Poulsen 2001). The 
activation of c-jun N-terminal kinase (JNK) pathway by IL-1β in β-cells (Welsh 1996; Major 
and Wolf 2001) might be the mechanism by which IL-1β induces β-cell apoptosis, since 
JNK as a member of mitogen activated protein kinase (MAPK) family transmit the stress 
and apoptotic signaling in many cells (Miyauchi, Takiyama et al. 2009). The inhibition of 
JNK pathway prevents the pancreatic β-cell from cytokine-mediated apoptosis 
(Ammendrup, Maillard et al. 2000; Bonny, Oberson et al. 2000; Bonny, Oberson et al. 
2001). It has been also shown that IL-1β induces apoptosis in β-cells through induction of 
Fas expression, whose signaling activation triggers apoptosis (Loweth, Williams et al. 
1998; Giannoukakis, Mi et al. 2000).  
A balance between IL1-β and IL-1Ra might be a crucial factor for the improvement 
of β-cell function in Type 2 diabetic patients. Treatment of these patients with IL-1Ra 
decreased the plasma level of HbA1c (Larsen, Faulenbach et al. 2007; Larsen, 
Faulenbach et al. 2009). The expression of IL-1Ra in these patients is reduced, where the 
production of IL-1β is induced by high glucose concentration in pancreatic β-cells, which 
indeed leads to impaired insulin secretion, diminishes β-cell proliferation, and induces β-
cell apoptosis (Poitout and Robertson 2002; Rhodes 2005; Donath and Mandrup-Poulsen 
2008; Dinarello, Donath et al. 2010). A protective effect of exogenous recombinant human 
(rh) IL-1Ra on high fat diet-induced hyperglycemia (Sauter, Schulthess et al. 2008) and on 
cultured human islets against IL-1β-mediated apoptosis triggered by glucose has been 
reported (Maedler, Spinas et al. 2001).  
Lipotoxicity along with elevated glucose concentration plays an important role in β-
cell destruction by production and secretion of IL-1β in diabetic patients (Federici, Hribal et 
al. 2001; Maedler, Sergeev et al. 2002).  
Another study in pancreatic islet β-cells demonstrated that IL-1β decreases the 
transcriptional activity of MafA (a pivotal transcription factor for β-cell function) followed by 
inhibition of insulin transcription, which leads to destruction in insulin biosynthesis and β-
cell dysfunction (Oetjen, Blume et al. 2007). 
Similar to glucose, low concentrations of IL-1β have a protective effect on human 
pancreatic β-cells through increase in glucose-stimulated insulin secretion (Maedler, 
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Figure 1. 3 Signaling events triggered by IL-1 family members in β-cells. Binding of IL-1α and 
IL1-β to IL-1RI triggers the downstream signaling. By activating of nuclear factor (NFκB) and 
mitogen activated kinases (MAPKs), IL-1β induces apoptosis in β-cells leading to type 2 diabetes 
mellitus. IL-1Ra is a competitive antagonist of IL-1 on IL-1RI. IL-1RII is an orphan receptor whose 
binding does not activate any downstream signaling cascade. The figure has been modified from 




 Tumor necrosis factor (TNF, known as TNFα) was introduced in 1975 as an 
endotoxin-induced glycoprotein. The new identified factor showed a haemorrhagic 
necrosis in transplanted sarcomas in mice (Carswell, Old et al. 1975). 10 years later the 
human tumor necrosis factor was cloned (Pennica, Hayflick et al. 1985). Activated 
macrophages and T-lymphocytes are the main source of TNFα production. They produce 
a 26 kDa pro-TNF molecule which is expressed in plasma membrane. A 
metalloproteinase, TNFα converting enzyme, (TACE, also known as ADAM-17) cleaves 
the extracellular domain of pro-TNF and releases a 17 kDa soluble molecule (Black, 
Rauch et al. 1997). Two distinct receptors have been identified for TNFα, TNFR1 
(TNFRSF1A, CD120a) and TNFR2 (TNFRSF1B, CD120b) which are expressed in 
different cell types (Al-Lamki, Wang et al. 2001). Despite similarity in extracellular 
cysteine-rich ligand-binding domain the intracellular domains of two receptors show no 
sign of homology, leading to distinct signal transduction pathways (Ledgerwood, Pober et 
al. 1999) (Fig. 1.4). TNFR1 has been suggested to be involved in pro-inflammatory and 
programmed cell death activated by TNFα, while TNFR2 might mediate the tissue repair 
and angiogenesis. TNFR1 is mainly sequestered in Golgi apparatus in resting cells. Its 
cell membrane-translocation sensitizes the cell to the action of TNFα (Bennett, Macdonald 
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Figure 1. 4 TNFα signaling pathways. TNFR appears as trimer in plasma membrane. TNFR1 
contains death domains (DD), the protein motifs which interact with other DDs. SODD (silencer of 
death domain) might prevent the TNFR1 signaling. Binding of TNFα to TNFR1 results in the 
release of SODD, leading to recruitment of TNFR-associated DD protein, which initiates the 
signaling by interacting to RIP-1 (receptor interacting protein-1) and TNFR-associated factor-2 
(TRAF2). The signal initiating complex is internalized and interacts with different signal proteins, 
including MAP3Ks (mitogen activated protein kinase kinase kinase), IKK (inhibitor of κB [IκB] 
kinase), and FADD (Fas-associated death domain protein). The activation of NFκB (nuclear factor 
κB) through IKK, JNK and AP-1 (activator protein-1) through MAP3Ks, and caspases through 
FADD result in cell pro-inflammatory and apoptotic signals. TNFR2 lacks the death domain but can 
interacts with TRAFs (Hsu, Huang et al. 1996; Takeuchi, Rothe et al. 1996; Ichijo, Nishida et al. 
1997; Nishitoh, Saitoh et al. 1998; Jiang, Woronicz et al. 1999; Jones, Ledgerwood et al. 1999; 
Yang, Lin et al. 2001; Blonska, Shambharkar et al. 2005). The figure has been modified from 
(Bradley 2008).   
 
 
 The role of TNFα along with some other pro-inflammatory cytokines have been 
clarified in the pathogenesis of Type 1 and Type 2 diabetes mellitus (Donath, Storling et 
al. 2003; Hotamisligil 2006; Shoelson, Herrero et al. 2007). Since, most of the type 2 
diabetic patients are obese and TNFα is highly expressed in adipose tissues of obese 
subjects, there might be a link between obesity and the development of insulin resistance, 
mediated by TNFα (Hotamisligil, Arner et al. 1995). In addition, the obese mice lacking 
either TNFα or its receptors do not show insulin resistance (Uysal, Wiesbrock et al. 1997). 


























































Page | 19  
 
white adipose tissue (WAT) beside inducing IL-6. By activation of sphingomyelinase TNFα 
increases the production of free fatty acids (FFA) and ceramides, the molecules that 
contribute to insulin resistance in peripheral tissues (Arner 2003). 
 The contribution of MAPKs in the insulin resistance induced by TNFα has been 
reported. In type 2 diabetic subjects the phosphorylation of p38MAPK in adipocytes and 
muscle accelerates the insulin resistance process and glucose intolerance by down 
regulation of GLUT-4 (glucose transporter type 4) expression (Carlson, Koterski et al. 
2003). TNFα mediates the Ser-Thr phosphorylation of IRS-1 (insulin receptor substrate-1) 
at Ser-307 residue through activation of the MAPK family members ERK and JNK (Rui, 
Aguirre et al. 2001; Aguirre, Werner et al. 2002). The MEK1/2-p42/44 MAPK pathway may 
mediate insulin resistance induced by TNFα in 3T3.L1 adipocytes (Engelman, Berg et al. 
2000). 
 The role of activated IKK (inhibitor of κB kinase) by TNFα in Ser-phosphorylation of 
IRS-1 has been also reported (Yuan, Konstantopoulos et al. 2001). The inhibition of IKK 
by salicylate reversed the obesity and diet-induced insulin resistance (Yuan, 
Konstantopoulos et al. 2001; Gao, Zuberi et al. 2003). 
 In addition to the involvement of TNFα in insulin resistance some reports clarified 
the contribution of TNFα in necrotic and apoptotic pancreatic β-cell death. In Type 1 
diabetes, the infiltrating cells might play a role in β-cell destruction by producing of 
cytokines TNFα, IFNγ, and IL-1 (Campbell, Iscaro et al. 1988; Pukel, Baquerizo et al. 
1988). A combination of these three cytokines has been reported to induce apoptosis in 
rat islets and βTC1 cells by forming hypodiploid nuclei and oligonucleosomal DNA 
fragmentation (Rabinovitch, Suarez-Pinzon et al. 1994; Iwahashi, Hanafusa et al. 1996). 
DNA strand breaks and apoptosis have been also observed in human pancreatic islet 
cells after prolonged exposure to a mixture of these cytokines (Delaney, Pavlovic et al. 
1997). Through TNFR1, TNFα executes downstream signaling of TRADD, FADD, 
caspase8 (FLICE: FADD-like interleukin-1 beta-converting enzyme), and ceramide whose 
activity result in apoptotic β-cell death (Ishizuka, Yagui et al. 1999). The involvement of 
TNFα in combination with IFNγ and IL-1β in the induction of apoptosis has been shown. 
Transfection of human pancreatic islets and rat insulin producing cell line (RINm5F) with 
the anti-apoptotic gen bcl-2 counteracted the apoptosis and β-cell destruction induced by 
these cytokines (Rabinovitch, Suarez-Pinzon et al. 1999; Saldeen 2000). 
 
1.2.c IFNγ 
 The interferon (IFN) was discovered as an agent who interferes with virus 
replication (Isaacs and Lindenmann 1957). Different members of this family were 
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classified according to their secreting cell type, but today they are classified into two 
types, type I and type II, according to receptor specificity and sequence homology. The 
type I consist of multiple subtypes such as IFNα, IFNβ, IFNω, and IFNτ. All members of 
type I IFN bind to a heterodimeric receptor IFNAR which is comprised of IFNAR1 and 
IFNAR2 chains (Liu 2005). IFNγ is the only member of type II IFN which has no structural 
relation to type I IFNs and binds to a different receptor, IFNGR (Gray and Goeddel 1982). 
Beside the immunomodulatory activities, the role of IFNγ in pancreatic β-cell survival and 
death has been reported along with other pro-inflammatory cytokines.   
 The IFNγ receptor (IFNGR) is comprised of two ligand-binding chains, IFNGR1 
and IFNGR2. Since both IFNGR chains lack the intrinsic kinase/phosphatase activity they 
need to recruit signaling machinery for signal transduction. The signaling pathway 
recruited by this receptor is a well-known pathway called JAK-STAT which is used by over 
50 cytokines, growth factors and hormones (Subramaniam, Torres et al. 2001). IFNγ is a 
noncovalent homodimer in its biologically active form and binds IFNGR1 in 2:2 binding 
stoichiometry (Ealick, Cook et al. 1991; Fountoulakis, Zulauf et al. 1992; Greenlund, 
Schreiber et al. 1993; Walter, Windsor et al. 1995; Bach, Tanner et al. 1996). The IFNγ: 
IFNGR1 complex interact with IFNGR2 (Kotenko, Izotova et al. 1995; Pestka, Kotenko et 
al. 1997). Ligand binding induces the autophosphorylation of JAK2 and consequently the 
transphosphorylation of JAK1 by JAK2 (Briscoe, Rogers et al. 1996). The activated JAK1 
phosphorylate IFNGR1 at Y440 which leads to the recruitment of STAT1 to the receptor 
(Greenlund, Farrar et al. 1994; Igarashi, Garotta et al. 1994; Greenlund, Morales et al. 
1995; Heim, Kerr et al. 1995). Stat1 is phosphorylated at Y701 probably by JAK2 (Briscoe, 
Rogers et al. 1996). The activated STAT1 dissociates from receptor as homodimers and 
enters the nucleus for further transcriptional activity. STAT1 binds DNA at IFNγ-activation 
site (GAS) elements which control the transcription of IFNγ-responsive genes (Decker, 









Figure 1. 5 IFNγ signaling. A conformational change occurs after ligand binding in IFNGR which 
allows the autophosphorylation and activation of JAK2. The activated JAK2 transphosphorylates 
and activates JAK1 which is responsible for the running of downstream signaling such as Stat1 
activation. The phosphorylated and homodimerized Stat1 translocates into the nucleus and binds 
to IFNγ-activation site (GAS) to initiates/suppress the expression of IFN-regulated genes. IRF-1 as 
a transcription factor which is regulated by IFNγ drives the next wave of transcription such as iNOS 
and IRF-2. After activation by IFNGR, IRF-1 translocates into the nucleus and binds to IFN-
stimulated response element (ISRE) and regulates the corresponding genes’ transcription. The 
alternative pathways triggered by IFNγ include the activation of protein-tyrosine kinase (PyK) 2, 
Phosphatidylinositide 3-kinase (PI3-K), Inhibitor of κB kinase (IKK), and Ca
2+
/calmodulin-dependent 
protein kinase (CAMK) II. The figure has been modified from (Schroder, Hertzog et al. 2004). 
 
 IFN-regulatory factor (IRF) family members are involved in IFNs signal cascades, 
of which IRF-1, IRF-2, and IRF-9 participate in IFNγ signaling (Sims, Cha et al. 1993; 
Harada, Takahashi et al. 1994). Stat1 and NF-κB dramatically increase IRF-1 transcription 
(Pine 1997). The activation of MEK1/ERK1/2 MAP kinase pahway (Hu, Roy et al. 2001; 
Gough, Sabapathy et al. 2007), and MKK6/p38 MAP kinase pathway by IFNγ have been 
reported (Sun and Ding 2006). Although the activation of JNK by IFNγ in macrophages 
has been observed (Valledor, Sanchez-Tillo et al. 2008) most of the reports show no 
activation of JNK by IFNγ (Platanias 2005; Gough, Sabapathy et al. 2007). The 
involvement of PI-3K and CamKII in IFNγ triggered signal transduction have also been 
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 The participation of IFNγ in β-cell dysfunction and death has been documented. 
Overxpression of IFNγ in a transgenic mice model leads to inflammatory destruction of 
islet β-cells (Sarvetnick, Liggitt et al. 1988). IL-1β, TNFα, and IFNγ alone did not induce 
lysis of islet cells but their combination resulted in β-cell dysfunction and death (Eizirik, 
Sandler et al. 1994; Suk, Kim et al. 2001; Liu, Cardozo et al. 2002; Thomas, Darwiche et 
al. 2002). Different pathways have been suggested for cooperative deleterious effect of 
these cytokines in β-cells. The combination of TNFα and IFNγ leads to β-cell death via up-
regulation of Fas expression (Dudek, Thomas et al. 2006; McKenzie, Dudek et al. 2006). 
The expression of SERCA (sarcoplasmic/endoplasmic reticulum Ca2+ ATPase) 2 in β-cells 
is inhibited after treatment with IFNγ + IL-1β which leads to ER (endoplasmic reticulum) 
depletion of Ca2+ store, ER stress and finally β-cell death (Cardozo, Ortis et al. 2005). The 
combination of IL-1β, TNFα, and IFNγ induces the expression and phosphorylation of 
Stat1 in pancreatic islet cells. The expression of Stat1 has also been observed in 
pancreatic islet of diabetic NOD mice which is co-localized with apoptotic β-cells. In 
addition transfection with phosphorylation defective Stat1 protects β-cells from death 
induced by IFNγ + TNFα (Suk, Kim et al. 2001; Kutlu, Cardozo et al. 2003). On the other 
hand the absence of Stat1 prevents β-cells from death induced by IFNγ + IL-1β 
(Gysemans, Ladriere et al. 2005). Stat1 deficient NOD mice were also protected from 
insulitis and diabetes (Kim, Kim et al. 2007). 
 Despite the Jak-Stat signaling pathway, IRF transcriptional activity is also triggered 
by IFNγ which exhibits a protective effect in β-cells in contrast to Stat signaling 
(Gysemans, Pavlovic et al. 2001). Regarding these reports IFNγ might play a dual role in 
β-cell destruction and survival.     
 
1.3 DLK 
Dual leucine zipper-bearing kinase (DLK) is a member of mixed lineage kinase (MLK) 
family and known as a mitogen-activated protein kinase kinase kinase (MAPKKK) which is 
expressed in brain and the peripheral nervous system (Holzman, Merritt et al. 1994; Hirai, 
Kawaguchi et al. 2005). Its expression has been also reported in primary murine islets and 
the β-cell line HIT (Oetjen, Lechleiter et al. 2006).  
 The MLK family is composed of five distinct members, designated MLK1, MLK2, 
MLK3, DLK (also called MUK and ZPK), and LZK (Leucine zipper-binding kinase), which 
share two common structural features: A hybrid catalytic domain similar to 
serine/threonine and tyrosine kinases, and two leucine/isoleucine motifs separated by a 
short spacer and a proline-rich COOH-terminal domain (Dorow, Devereux et al. 1993; 
Hirai, Izawa et al. 1996; Sakuma, Ikeda et al. 1997; Rasmussen, Rusak et al. 1998). 
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According to their structure MLK1, MLK2, and MLK3 form one closely related subfamily 
whereas DLK and LZK form another distinct subfamily (Holzman, Merritt et al. 1994; 
Sakuma, Ikeda et al. 1997). The first subfamily shows a 70% sequence identity in highly 
conserved kinase catalytic and leucine zipper (LZ) domains and possess an SH3 (SRC 
homology 3) domain in their NH2-terminal region. DLK and LZK show a sequence identity 
more than 90% in their kinase catalytic and dual LZ domains which are only 36% identical 
to those of MLK2 and MLK3. DLK and LZK lack the SH3 domain and have a structurally 
different region than of those of MLK2 and MLK3 close to COOH-terminal (Teramoto, 
Coso et al. 1996; Nagata, Puls et al. 1998) (Fig. 1.6). Regarding to distinct structural 
features, different subcellular localization and substrates have been proposed for these 
two subfamilies  of MLKs, where both DLK and MLK3 utilize MKK7 as a substrate, but 
unlike MLK3, the involvement of DLK in phosphorylation and activation of MKK4 is not 




                           
Figure 1. 6 Schematic structure of the MLK family members. The first subfamily including 
MLK1, MLK2, and MLK3 possess an SH3 domain in their N-terminal region, a catalytic kinase 
domain, one LZ domain, and a CRIB (Cdc2/Rac interactive binding) domain within the C- terminal 
of the peptide. The second subfamily including DLK and LZK lack the SH3 domain in their N-
terminal and the CRIB domain within their C-terminal, and possess a dual LZ which is separated by 
a spacer sequence. The figure has been modified from (Gallo and Johnson 2002). 
 
 
 The regulatory role of DLK in cell proliferation, differentiation and survival has been 
studied. DLK expression is not ubiquitously distributed during mouse embryogenesis and 
is mostly restricted to central nervous system, epithelia of the skin, intestine, pancreas, 
and kidney, manifesting the areas undergoing terminal cell differentiation (Nadeau, 
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growth and neuronal migration of the developing cerebral cortex (Brancho, Ventura et al. 
2005; Hirai, Cui de et al. 2006; Bisson, Tremblay et al. 2008). DLK also has been reported 
to be involved in tissue regeneration (Matsui, Sarkar et al. 1996; Douziech, Grondin et al. 
1998). Overexpression of DLK was shown to inhibit cell growth in fibroblasts and primary 
human keratinocytes (Bergeron, Douziech et al. 1997; Germain, Fradette et al. 2000). In 
addition, DLK induces apoptosis in a neuronal cell line, a fibroblast cell line and HIT cells 
which is dependent on its enzymatic activity (Xu, Maroney et al. 2001; Parkash, Chaudhry 
et al. 2005; Rhodes 2005; Plaumann, Blume et al. 2008). On the other hand a recently 
reported study demonstrated the participation of DLK in the proliferation of WI-38 human 
fibroblast cell line by modulating the expression of cell cycle regulating proteins (Daviau, 
Couture et al. 2011). Oligomerization and homodimerization have been suggested as a 
mechanism for DLK activation. The calphostin activated transglutaminase triggered the 
oligomerization and activation of overexpressed DLK (Robitaille, Daviau et al. 2008). On 
the other hand, dephosphorylation of DLK by calcineurin, a calcium/calmodulin dependent 
phosphatase, might be a regulating mechanism of DLK activity, where inhibition of 
calcineurin by immunosuppressive drugs cyclosporin A (CsA) and tacrolimus enhanced 
DLK-induced phosphorylation of the substrate casein and DLK itself (Oetjen, Lechleiter et 
al. 2006; Plaumann, Blume et al. 2008).  
 CRE- (cAMP response element) binding protein (CREB) is a transcription factor 
that has been implicated in the survival and maintenance of β-cells (Oetjen, Diedrich et al. 
1994; Oetjen, Grapentin et al. 2003). The transcriptional activity of CREB is induced by 
different signals such as cAMP, calcium, extracellular signal-regulated kinase (ERK1/2) 
and p38 MAPK (Habener, Miller et al. 1995; Mayr and Montminy 2001). Mice with β-cell 
specific inactivated CREB develops diabetes due to reduced proliferation and increased 
β-cell apoptosis (Jhala, Canettieri et al. 2003). The inhibitory effect of DLK on membrane 
depolarization-induced transcriptional activity of CREB has been reported in a β-cell line 
(Oetjen, Lechleiter et al. 2006) which might suggest a role for DLK in the pathogenesis of 
diabetes.  
All members of MLK family including DLK have been proposed to act as a MAPK 
kinase kinase in the pathway leading to activation of JNK/SAPK (c-Jun N-terminal 
kinase/stress activated protein kinase) (Fan, Merritt et al. 1996; Hirai, Izawa et al. 1996; 
Rana, Gallo et al. 1996; Tibbles, Ing et al. 1996; Hirai, Katoh et al. 1997; Sakuma, Ikeda 
et al. 1997; Nagata, Puls et al. 1998). It is assumed that JNK triggers the dissociation of 
DLK from scaffold protein JIP (JNK interacting protein) which leads to DLK 
homodimerization, autophosphorylation and activation (Leung and Lassam 2001; 
Nihalani, Meyer et al. 2001; Nihalani, Wong et al. 2003). The JNK/SAPK is well known as 
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stress inducing protein and is activated as one of the three major MAPKs, which is 
induced by upstream MKK4 and MKK7. Different cellular stress stimuli trigger JNK 
pathway, including ultraviolet light, heat shock, osmotic shock, protein synthesis inhibitors 
and different kinds of cytokines such as TNFα and Fas (Hibi, Lin et al. 1993; Galcheva-
Gargova, Derijard et al. 1994; Kyriakis, Banerjee et al. 1994; Toyoshima, Moriguchi et al. 
1997). 
 
1.4 The aim and objectives of the study 
The hypothesis of this study is that DLK participates in the pathogenesis of type 2 
diabetes. The regulation of DLK by prediabetic signals (pro-inflammatory cytokines TNFα, 
IL-1β, and IFNγ) was investigated employing a phosphorylation specific antibody against 
DLK.  
The subcellular localization of DLK driven by prediabetic signals was studied 
through the interaction of DLKwt and mutant (NLS1, NLS2, PP) proteins with nuclear 
receptors, which are crucial for the nuclear translocation of proteins carrying NLS (nuclear 
localization signal), as well as in vitro experimentation (immunocytochemistry) in HIT cells.  
The role of DLK in diet-induced diabetes was investigated in C57BL/6J wild-type 
and DLK-heterozygote mice under different diet.  
Since the global DLK knock-out mice die perinataly, a targeting vector was 
designed and generated to produce β-cell specific DLK knock-out mice, using BAC 
(bacterial artificial chromosome)-recombineering and gap-repair strategy.   
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2. Materials and methods 
2.1. Equipment 
2.1.a. Apparatus 
Autoclave Bioclav, Schütt Labortechnik, Goettingen, Germany 
MediTech service GmbH, Norderstedt, Germany 
AutoLumat  
luminometer 
LB 953, E&G Berthold, Bad Wildbach, Germany 
Balances Sartorius AG, Goettingen, Germany 
Cell culture hood Herasafe - Heraeus, Langenselbold, Germany 
Centrifuge rotors JA-20/JA-17/JA-14, Ti 70, Beckmann GmbH, Germany 
Centrifuges Beckman GS-6–Beckman Coulter GmbH, Krefeld, Germany  
Beckman J2-21– Beckman Coulter GmbH, Krefeld, Germany 
Beckman L8-70M Ultracentrifuge, Beckman Coulter GmbH, Krefeld, 
Germany 
Eppendorf 5415D, Eppendorf GmbH, Hamburg, Germany 
Eppendorf 5424R, Eppendorf GmbH, Hamburg, Germany 
Rotina 35R, Andreas Hettich GmbH & Co. KG, Tuttlingen, Germany 
Cell Disrupter Branson Sonifyer® B15 – Heinemann Ultraschall- u. Labortechnik, 
Schwäbisch Gmünd, Germany 
Bandelin UW 2200, Berlin, Germany 
DNA Sequencer ABI PRISM 3100 Genetic Analyzer – Applied Biosystems, Darmstadt, 
Germany 
ABI PRISM 7900 HT Sequence Detection System – Applied 
Biosystems, Darmstadt, Germany 
Electrophoresis 
power supplier 
Biometra® Standard Power Pack P25 – Whatman Biometra, 
Goettingen, Gemany 
Bio-Rad Power PAC Basic, Munich, Germany 
Bio-Rad Power PAC HC, Munich, Germany 
Electrophoresis 
chamber (DNA) 
Carl Roth, Karlsruhe, Germany 





Electrophoresis chamber SE 600 – Hoefer Scientific Instruments,  
San Francisco, USA   
Mini-protein Tetra system, Bio-Rad, Munich, Germany 
Mighty Small SE 250/SE 260, Hoefer, San Francisco, USA 
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Mighty Small SE245 Dual Gel Caster, glasses, spacer, combs – 
Hoefer Scientific Intsruments, San Francisco, USA 
Electroporater Micropulser, Bio-Rad, Munich, Germany 
Electroporation 
Cuvettes 
25×1mm gap, PeQLab Biotechnology, Erlangen, Germany 
Fluorometer 
Fusion 
Canberra-Packard, Dreieich, Germany 
Gel Dryer  Gel Dryer Model 583, Bio-Rad, Munich, Germany 
Immunoblot 
detection device  
Chemi Genius - Bio Imaging System, SYNGENE, Cambridge, UK 
Versa doc Imaging System, Bio-Rad, Munich, Germany 
Incubators Bacteria Incubator - Heraeus , Langenselbold, Germany 
CO2-Incubator BB15 - Heraeus, Langenselbold, Germany  
Micro pipettes Eppendorf, Hamburg, Germany 
Microscope Zeiss Axiovert 25 microscope – Carl Zeiss AG, Oberkochen, Germany 
Zeiss Axiovert 200m-Apotom – Carl Zeiss Ag, Oberkochen, Germany 
PCR cycler PCR cycler T-Gradient – Biometra, Goettingen, Germany 
PCR system 9700 - Applied Biosystems, Darmstadt, Germany 
PTC-200 Peltier Thermal Cycler – Biozym, Hess, Oldendorf, Germany 
pH meter pH 523, Schütt Labortechnik, Goettingen, Germany 
766 calimatic Knick, Berlin, Germany 
Rocking platform Biometra, Goettingen, Germany 
Duomax 1030 – Heidolph Instruments GmbH & Co.KG, Schwabach, 
Germany 
Rolling platform TRM-V – IDL, Nidderau, Germany 
 
Rotator Rotator GFL 3025 – Gesellschaft für Labortechnik mbH, Burgwedel, 
Germany 
Spectrophotometer Eppendorf Biometer, Eppendorf, Hamburg, Germany 
Nanodrop spectrophotometer-ND1000, Wilimington, USA 
Semi-dry transfer 
device 
Bender & Hobein, Zurich, Switzerland 
Shaking platform Certomat®R shaking platform – Sartorius, Goettingen, Germany 
GFL - RM5 U-30 - CAT, GFL, Burgwedel, Germany  
Thermomixer Eppendorf Comfort, Eppendorf, Hamburg, Germany 
Transilluminator Biometra Ti1 - Biometra, Goettingen, Germany 
Tube Sealer Beckmann Tube Sealer – Beckmann GmbH, Munich, Germany 
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Vacuum Pump 
Vacuum Chamber  
KnF Laboport, Neuberger, Germany 
Bachofer, Reutlingen, Germany 
Waterbath W. Krannich GmbH, Goettingen, Germany 
HAAKE DC3, Goettingen, Germany 
Circulating water bath, Julabo, Seelbach, Germany 
 
2.1.b. Consumables 
Plates & Cell culture dishes 10 cm agar plate, Sarstedt, Nuembrecht, Germany 
6 cm cell culture dishes, Sarstedt, Nuembrecht, 
Germany 
15 cm cell culture dishes, Sarstedt, Nuembrecht , 
Germany  
BD Falcon™ 15 cm cell culture dishes, Schuett24 
GmbH, Goettingen, Germany 
6-well plate, Sarstedt, Nuembrecht, Germany 
6-well plate, Greiner Bio-One, Frickenhausen, 
Germany 
96-well Millipore plates, Millipore GmbH, 
Schwalbach, Germany 
Coverslips Marienfield-Superior, Lauda-Koenigshofen, Germany 
Disposable cell scraper Sarstedt, Nuembrecht, Germany 
Dialysis tubes GIBCO BRL, Karlsruhe, Germany  
Glass pipettes WU, Mainz,Germany 
Gloves Paul Hartmann AG, Heidenheim, Germany 
Meditrade Nitril-gloves, Kiefersfelden, Germany 
Microscope slides 75x25mm Karl Hecht, Sondheim/Rhoen, Germany 
Nitrocellulose membrane (0.45µm) Hybond™, ECL™, Amersham Biosciences, 
Freiburg, Germany 
Parafilm Parafilm® M – Brand GmbH & Co KG, Wertheim, 
Germany 
Pasteur pipettes Carl Roth, Karlsruhe, Germany 
Pipette tips Sarstedt, Nuembrecht, Germany 
Quick Seal Tubes Beckmann GmbH, Munich, Germany 
Spectrophotometer cuvettes 
(plastic) 
Sarstedt, Nuembrecht, Germany 
Spectrophotometer cuvettes (quartz) Sarstedt, Nuembrecht, Germany 
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Syringes BD Discardit II, Beckton Dickinson, Heidelberg, 
Germany 
Syringe filters Sartorius, Goettingen, Germany 
Syringe needles Sterican, B/BRAUN, Melsungen, Germany 
Tubes 15 ml red-cap tubes, Sarstedt, Nuembrecht, 
Germany  
50 ml red-cap tubes, Sarstedt, Nuembrecht, 
Germany 
0.5, 1, and 2 ml eppendorf tubes, Eppendorf, 
Hamburg, Germany 
Ultracentrifuge tubes Beckman Coulter GmbH, Krefeld, Germany 




37% formaldehyde – Carl Roth, Karlsruhe, Germany  
99.5% glycerol – Carl Roth, Karlsruhe, Germany  
Acetic acid – Sigma-Aldrich, Seelze, Germany  
Acrylamide/Bis – Bio-Rad, Munich, Germany  
Agar – Carl Roth, Kralsruhe, Germany  
Agarose (electrophoresis grade) – Carl Roth, Karlsruhe, Germany  
Ammoniumpersulphate (APS) – Carl Roth, Karlsruhe, Germany  
Ampicillin – Sigma-Aldrich, Seelze, Germany 
Amylose Resin – BioLabs, Ipswich, USA 
Arabinose – Sigma-Aldrich, Seelze, Germany 
ATP – Applichem, Darmstadt, Germany 
β-Mercaptoethanol – Carl Roth, Karlsruhe, Germany  
Boric acid – Carl Roth, Karlsruhe, Germany  
Bovine serum albumin (BSA) – Applichem, Darmstadt, Germany  
Bradford reagent – Bio-Rad, Munich, Germany 
Bromophenol blue – Sigma-Aldrich, Seelze, Germany  
BSA fatty acid free – PAA, Coelbe, Germany  
Cesium chloride (CsCl) – Applichem, Darmstadt, Germany  
Chloramphenicol – Carl Roth, Karlsruhe, Germany 
Chloroform – Applichem, Darmstadt, Germany  
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Collagenase P – Roche, Mannheim, Germany 
Coomassie brilliant blue – Sigma-Aldrich, Seelze, Germany  
Cyclosprin A – Sigma-Aldrich, Seelze, Germany  
DEAE-Dextran – Amersham, Glattbrugg, Switzerland  
Dimethyl sulfoxide (DMSO) – Sigma-Aldrich, Seelze, Germany  
Deoxynucleoside triphosphates (dNTPs) – Fermentas, St. Leon-Rot, Germany  




) – Carl Roth, Karlsruhe, Germany  




) – Carl Roth, Karlsruhe, Germany  
Dithiothreitol (DTT) – Applichem, Darmstadt, Germany  
D-Luciferin – P.J.K., Kleinbittersdorf, Germany  
D-Saccharose – Carl Roth, Karlsruhe, Germany  
EDTA – Carl Roth, Karlsruhe, Germany  
EGTA – Carl Roth, Karlsruhe, Germany  
Ethanol – Carl Roth, Karlsruhe, Germany  
Ethidium bromide – Applichem, Darmstadt, Germany  
Fetal calf serum – Biochrom, Berlin, Germany  
Forskolin – Sigma-Aldrich, Seelze, Germany  
Glucose – Carl Roth, Karlsruhe, Germany  
Glutathione agarose – Sigma-Aldrich, Seelze, Germany  
Glycine – Carl Roth, Karlsruhe, Germany  
Glycylglycine – Applichem, Darmstadt, Germany  
HEPES – Carl Roth, Karlsruhe, Germany  
His bind Resin – Novagen, Darmstadt, Germany 
Horse serum – GIBCO BRL, Karlsruhe, Germany  
Hydrochloric acid (HCl) – Carl Roth, Karlsruhe, Germany 
Interferon gamma (IFNγ) – Biomol, Hamburg, Germany 
Interleukin 1-betta (IL-1β) – Biomol, Hamburg, Germany 
Isoamylalcohol – Applichem, Darmstadt, Germany  
Isopropanol – Sigma-Aldrich, Seelze, Germany  
Isopropyl-β-D-thiogalactoside (IPTG) – Applichem, Darmstadt, Germany  
Kanamycin Sulfate – Carl Roth, Karlsruhe, Germany 
L-Glutathione – Sigma-Aldrich, Seelze, Germany  
Lysozyme – Sigma-Aldrich, Seelze, Germany  
Magnesium chloride (MgCl
2
) –Carl Roth, Karlsruhe, Germany  
Magnesium sulphate (MgSO
4
) – Carl Roth, Karlsruhe, Germany  
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Metafectene – Biontex, Munich, Germany  
Methanol – Carl Roth, Karlsruhe, Germany  
Milk Powder – Carl Roth, Karlsruhe, Germany 
Nonidet-P40 – Applichem, Darmstadt, Germany 
Oligofectamine – Invitrogen, Karlsruhe, Germany 
Polyethylene glycol 6000 (PEG 6000) – Applichem, Darmstadt, Germany  
Penicillin / Streptomycin – GIBCO BRL, Karlsruhe, Germany  
Pepton from casein – Carl Roth, Karlsruhe, Germany  
Phenol (Tris saturated) – Biomol, Hamburg, Germany  
Phenylmethylsulfonylfluorid (PMSF) – Applichem, Darmstadt, Germany  
Phosphatase Inhibitor (PhosStop) – Roche, Mannheim, Germany  
Ponceau S solution – Applichem, Darmstadt, Germany  
Potassium chloride (KCl) – Carl Roth, Karlsruhe, Germany  




) – Carl Roth, Karlsruhe, Germany  
Protease Inhibitor – Roche, Mannheim, Germany 
Ribonuclease A – Applichem, Darmstadt, Germany 
Sephadex G50 – Amersham Biosciences, Freiburg, Germany 
Silver nitrate (AgNO
3
) – Sigma-Aldrich, Seelze, Germany  





) – Carl Roth, Karlsruhe, Germany 
Sodium chloride (NaCl) – Carl Roth, Karlsruhe, Germany 




) – Carl Roth, Karlsruhe, Germany 
Sodium dodecylsulphate (SDS) – Carl Roth, Karlsruhe, Germany 







) – Applichem, Darmstadt, Germany  
Tetramethyethylenediamine (TEMED) – Merck, Darmstadt, Germany  
Tris – Carl Roth, Karlsruhe, Germany 
Triton X100 – Carl Roth, Karlsruhe, Germany 
Trypsin / EDTA – Biochrom, Berlin, Germany  
Tumor Necrosis Factor-α (TNFα) – Biomol, Hamburg, Germany 
Tween 20 – Carl Roth, Karlsruhe, Germany 
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2.2.b. Stock solutions and buffers 
2.2.b.I. Stocks 
All stock solutions were prepared in double-destilled water, exceptions are mentioned. 
Ampicillin* 10% (w/v) 1 g / 10 ml 
APS**    10 % (w/v) 1 g / 10 ml 
Chlorophorm / isoamylalcohol 1/24 (v/v) 1 ml / 24 ml 
Chloramphenicol** 3.4% (w/v) 34 mg /ml 99% EtOH 
Cyclosporin A*** 830 µM 1 mg in 0.1 ml 99% EtOH, and 20 µl Tween 80 
Dithiothreitol (DTT)** 1 M 1.542 g / 10 ml 
EDTA pH 8.0 0.5 M 46.53 g / 250 ml 
EGTA pH 8.0 180 mM 3.423 g / 50 ml 
Ethidium Bromide 10 mg/ml 100 mg / 10 ml 
Forskolin** 10 mM 1 mg / 243.6 µl DMSO 
HEPES pH 7.5 1 M 59.58 g / 250 ml 
Glucose 0.5 M 9 g / 100 ml 
Glycine 1 M 7.507 g / 100 ml 
Glycylglycine pH 7.8 0.5 M 3.303 g / 50 ml 
Kanamycine** 5% (w/v) 0.5 g / 10 ml 
KCl 2 M 2.98 g / 20 ml 
K2HPO4 0.5 M  4.35 g / 50 ml  
KH2PO4 100 mM 3.402 g / 250 ml 
MgCl2 1 M 5.08 g / 25 ml 
MgSO4  1 M 12.324 g / 50 ml 
NaCl 0.5 M 0.292 g / 10 ml 
Na2HPO4 75 mM  1.33 g / 100 ml 
NaH2PO4 75 mM  1.33 g / 100 ml 
NaOH  1 N 4 g / 100 ml 
Penicillin/Streptomycin** 10,000 U/ml     10,000 µg/ml (ready to use solution) 
PhosStop** 10x according to the manufacturer’s instruction 
PMSF** 200 mM 348 mg / 10 ml 99%-ethanol 
Protease inhibitor** 7x according to the manufacturer’s instruction 
RNase** 0.01% (w/v) 0.1 mg/ml 
Sodium dodecyl sulphate (SDS) 10% (w/v) 25g / 250 ml 
Tris/HCl 1 M 60.57 g / 500 ml 
Stock solutions were stored at room temperature. 
* Stored at -80°C 
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** Stored at -20°C 
*** Stored at +4°C 
Different pHs were adjusted for Tris-base and HEPES using HCl. 
 
2.2.b.II. Buffers 
Total volume for all buffers was adjusted by double-destilled water. 
PBS pH 7.4 1x 1 L 
NaCl 140 mM 8.00 g 
KCl 2.5 mM 0.20 g 
Na2HPO4 8.1 mM 1.44 g 
KH2PO4 1.5 mM 0.24 g 
pH was adjusted by HCl. 
 
TBS 1x 1L 
Tris/HCl (pH 8.0) 10   mM 10ml of 1M 
NaCl 150 mM 30ml of 5M 
 
TAE-buffer 1x 1 l 
Tris 40 mM 4.84 g 
EDTA 1   mM 2 ml of 0.5 M stock 
Acetic acid 20 mM 1.14 ml 
 
TBE-buffer 1x 1L 
Tris 89 mM 10.8 g 
Boric Acid 89 mM 5.5 g 
EDTA (pH 8.0) 2   mM 4 ml of 0.5 M stock 
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2.2.c. Kits 
Big Dye® Terminator v1.1 Cycle Sequencing Kit – Applied Biosystems, Darmstadt, 
Germany 
Bradford Dye Reagent for Protein Assays – Biorad, Munich, Germany 
Easy Pure® DNA purification kit – Biozym, Hess.-Oldendorf, Germany 
Geno Pure plasmid maxi kit – Roche, Mannheim, Germany 
High-pure plasmid isolation kit – Roche, Mannheim, Germany 
Hi-pure plasmid maxiprep kit – Invitrogen, Karlsruhe, Germany 
Hi-pure plasmid miniprep kit – Invitrogen, Karlsruhe, Germany 
Lumi-lightplus Western Blotting Analysis System – Roche, Mannheim, Germany 
NucleoBond® BAC 100 – Macherey-Nagel, Dueren, Germany 
Vectashield® Mounting Medium with DAPI – Vector Laboratories, Burlingame, USA 
 
2.3. Biological material 
2.3.a. Bacterial strains 
 Chemically competent Escherichia coli strain DH5α and electro-competent 
Escherichia coli strain Top10 were used for plasmid amplification and expression of 
recombinant GST-fused proteins. Electro-competent Escherichia coli strain BL-21 was 
used for expression of recombinant His-tagged proteins. Electro-competent Escherichia 
coli strain K12Δ was used for expression of recombinant MBP-fused proteins. 
 Electro-competent Escherichia coli strains SW102, SW105, and SW106 were used 
for BAC recombineering experiments. 
 
2.3.b. Eukaryotic cell line 
 Hamster insulinoma tumor cells, clone HIT-T15, are an insulin-producing beta-cell 
line established by simian virus 40 transformation of pancreatic islet cells from Syrian 
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2.3.c. Prokaryotic culture and media 
LB medium  1L 
NaCl 1% (w/v) 10 g 
Pepton 1% (w/v) 10 g 
Yeast extract 0.5% (w/v) 5 g 
Antibiotic*   
* Final concentration for Ampicillin is 50 µg/ml and for Kanamycin is 15 µg/ml 
 The LB medium was autoclaved and stored at room temperature. Antibiotic was 
added freshly before use. 
 Bacteria were cultured in LB-medium supplemented with appropriate antibiotic, 
using a shaking platform agitating at a range of 150-220 rpm, at 32°C or 37°C depending 
on the experiment.   
 LB-antibiotic agar plates were prepared by using LB medium containing 1.5% (w/v) 
agar. The solution was autoclaved for 20 min at 121°C. After cooling to 50°C the 
appropriate antibiotic was added and the LB-antibiotic agar was poured into 10 cm dishes. 
The agar plates were solidified at room temperature and stored at 4°C. 
  
2.3.d. Eukaryotic culture and media 
 
RPMI complete  500 ml 
RPMI Medium  420 ml 
fetal calf serum 10% (v/v) 50  ml 
horse serum 5%   (v/v) 25  ml 
Penicillin / streptomycin 1%   (v/v) 5    ml 
The RPMI complete medium was stored at 4°C. 
 
 One patch of the frozen HIT-T15 cells was thawed at 37°C and cultured in RPMI 
complete medium. The cells were incubated at 37°C in a CO
2
-incubator with 95% (v/v) 
humidity and 5% (v/v) CO
2
. The cells were split once a week at full confluence into 15-cm 
dishes. After washing once with phosphate-buffered saline (PBS), the cells were 
trypsinized for 3-5 min with 3 mL trypsin / EDTA at 37°C. The reaction was stopped by 
addition of 7 mL RPMI complete medium. Cells were detached from the dish by tapping at 
the bottom and the wall, collected in the medium, centrifuged for 2 min at 800 rpm, and 





. After three days the medium was renewed. The cells from a confluent dish 
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were collected in RMPI complete medium, transferred to the RMPI medium containing 
50% FCS (fetal calf serum) and 10% DMSO (dimethyl sulfoxide), and frozen at -80°C for 
the later culture.  
 
2.3.e. Plasmids and Oligonucleotides  
2.3.e.I. Expression constructs 
An overview of all expression vectors used in the present work is listed in Table 1. 
All basic expression vectors for mammalian or bacterial expression are listed in Table 2. 
 Flag-DLK wild-type construct encodes the full length of mouse DLK. The coding 
sequence was cloned into pcDNA3.1 expression vector using HindIII and XhoI restriction 
enzymes. This construct encodes 888 amino acids of full length DLK (Holzman, Merritt et 
al. 1994). The Flag epitope (DYKDDDDK) was inserted between amino acids one and two 
of all constructs carrying the Flag epitope, using a modified primer (Holzman, Merritt et al. 
1994). 
 Flag-DLK K185A construct encodes the full length of mouse DLK with a point 
mutation where Lysine-185 residue was replaced by Alanine. The coding sequence was 
cloned into pcDNA3.1 expression vector at the restriction sites of HindIII and XhoI 
(Holzman, Merritt et al. 1994). 
 Flag-DLK S298A construct encodes the full length of mouse DLK with a point 
mutation where Serine-298 residue was replaced by Alanine. The coding sequence was 
cloned into pcDNA3.1 expression vector at the restriction sites of HindIII and XhoI (this 
study). 
 Flag-DLK S302A construct encodes the full length of mouse DLK with a point 
mutation where Serine-302 residue was replaced by Alanine. The coding sequence was 
cloned into pcDNA3.1 expression vector at the restriction sites of HindIII and XhoI (this 
study). 
 Flag-DLK S298A/S302A construct encodes the full length of mouse DLK with two 
point mutations where Serine-298 and Serine-302 residues were replaced by Alanine. The 
coding sequence was cloned into pcDNA3.1 expression vector at the restriction sites of 
HindIII and XhoI (this study). 
 Flag-DLK PP construct encodes the full length of mouse DLK with two point 
mutations where Leucine-437 and -463 residues were replaced by Proline residues. The 
coding sequence was cloned into the expression vector pcDNA3.1 at the restriction sites 
of HindIII and XhoI (Nihalani, Merritt et al. 2000). 
 Flag-DLK NLS1 construct encodes the full length of mouse DLK with two point 
mutations where Lysine-186 and Arginine-188 residues were replaced by Alanine 
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residues. The coding sequence was cloned into the expression vector pcDNA3.1 at the 
restriction sites of HindIII and XhoI (Walbach M, medical thesis, Goettingen 2000). 
 Flag-DLK NLS2 construct encodes the full length of mouse DLK with three point 
mutations where Lysine-196, Arginine-199 and Lysine-200 were replaced by Alanine 
residues. The coding sequence was cloned into the expression vector pcDNA3.1 at the 
restriction sites HindIII and XhoI (Walbach M, medical thesis, Goettingen 2000). 
 hIP-DLK NLS2 construct encodes the full length of mouse DLK NLS2 mutant 
under the control of human insulin promoter (hIP). The coding sequence was cloned into 
expression vector pcDNA5/FRT at the restriction sites of HindIII and XhoI. The promoter 
was cloned upstream to the coding sequence at the restriction site of HindIII. hIP-DLK 
NLS2 fragment can be cut out of the vector by XhoI and NheI restriction digest (this 
study). 
 PGK-DLK NLS2 construct encodes the full length of mouse DLK NLS2 mutant 
under the control of ubiquitously expressed promoter PGK. The coding sequence was 
cloned into expression vector pcDNA5/FRT at the restriction sites of HindIII and XhoI. The 
promoter was cloned upstream to the coding sequence at the restriction sites of HindIII 
and NheI (this study).   
 pGEX-DLK NLS wild-type, 1, and 2 mutants constructs encode a truncated form of 
mouse DLK comprising amino acids 140-285, which is N-terminally fused to GST 
(glutathione s-transferase). The coding sequences were cloned into the bacterial 
expression vector pGEX-6p1 at the restriction sites of SmaI and XhoI (this study).  
 pET-DLK NLS wild-type, 1, and 2 mutants constructs encode a truncated form of 
mouse DLK comprising amino acids 140-285, which is N-terminally fused to 6xHis 
cassette  (Histidine). The coding sequences were cloned into the bacterial expression 
vector pET 28a+ at the restriction sites of BamHI and SalI (this study). 
 pMAL-DLK NLS wild-type, 1, and 2 mutants constructs encode a truncated form of 
mouse DLK comprising amino acids 140-285, N-terminally fused to MBP (Maltose Binding 
Protein) (MBP-DLK). The coding sequences were cloned into the bacterial expression 
vector pMAL-c2x at the restriction sites of BamHI and SalI (this study).  
 pMAL-DLK KNLSLZ (consists of the catalytic region, NLS, and the leucine zipper 
region of DLK) wild-type, 1, and 2 mutants constructs encode a truncated form of mouse 
DLK comprising amino acids 140-517, which is N-terminally fused to MBP. The coding 
sequences were cloned into the bacterial expression vector pMAL-c2x at the restriction 
sites of BamHI and SalI (this study).  
 The expression construct GAL4-CBP encodes the full-length CBP fused C-
terminally to the DNA-binding domain of GAL4 (Oetjen, Thoms et al. 2005).  
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 G5E1B-Luc (Kruger, Schwaninger et al. 1997) expressing luciferase contains five 
repeats of the enhancer element, identified in yeast as binding site for the yeast 
transcription factor GAL4 (Webster, Jin et al. 1988), upstream to the viral E1B TATA box 
(Lillie and Green 1989; Liu and Green 1990). 
 CRE-Luc expresses luciferase reporter gene under the control of four copies of 
CRE of the rat somatostatin gene promoter (Oetjen, Diedrich et al. 1994).  
pGFPtpz-cmv® vector (Caberra-Packard, Dreieich, Germany) was used as internal 
control for luciferase reporter-gene assays. This expression vector encodes the green 






Table 1. Expression Constructs  
This table summarizes all constructs used in the present study. The providers of the 
constructs are mentioned in the footprint of the table.  
Name Source Vector Note 
DLK wild-type1 Mus musculus pcDNA3.1 Flag-tag full length 
DLK K185A1 Mus musculus pcDNA3.1 Flag-tag 
Lys185      Ala  
DLK S298A2 Mus musculus pcDNA3.1 Flag-tag 
Ser298      Ala 
DLK S302A2 Mus musculus pcDNA3.1 Flag-tag 
Ser302      Ala 
DLK S298A/S302A2 Mus musculus pcDNA3.1 Flag-tag 
Ser298      Ala 
Ser302      Ala 
DLK PP4 Mus musculus pcDNA3.1 Flag-tag 
Leu437     Ala 
Leu463     Ala 
DLK NLS13 Mus musculus pcDNA3.1 Flag-tag 
Lys186     Ala 
Arg188     Ala 
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DLK NLS23 Mus musculus pcDNA3.1 Flag-tag 
Lys196     Ala 
Arg199     Ala 
Lys200     Ala 
hIP-DLK NLS2* Mus musculus pcDNA5/FRT Flag-tag full length 
PGK-DLK NLS2* Mus musculus pcDNA5/FRT Flag-tag full length 
GST-DLK NLS wt* Mus musculus pGEX-6p1 aa 140-285 
GST-DLK NLS1* Mus musculus pGEX-6p1 aa 140-285  
GST-DLK NLS2* Mus musculus pGEX-6p1 aa 140-285 
His-DLK NLS wt* Mus musculus pET-28a+ aa 140-285 
His-DLK NLS1* Mus musculus pET-28a+ aa 140-285 
His-DLK NLS2* Mus musculus pET-28a+ aa 140-285 
MBP-DLK NLS wt* Mus musculus pMAL-c2x aa 140-285 
MBP-DLK NLS1* Mus musculus pMAL-c2x aa 140-285 
MBP-DLK NLS2* Mus musculus pMAL-c2x aa 140-285 
MBP-DLK KNLSLZwt* Mus musculus pMAL-c2x aa 140-517 
MBP-DLK KNLSLZ1* Mus musculus pMAL-c2x aa 140-517 
MBP-DLK KNLSLZ2* Mus musculus pMAL-c2x aa 140-517 
GAL4-CBP2   Full length 
CRE-Luc2    
 Generated in this work 
1. Generated by (Holzman, Merritt et al. 1994) 
2. Generated by Elke Oetjen 
3. Generated by Manuel Walbach 
4. Generated by (Nihalani, Merritt et al. 2000) 
  
pcDNA3.1, pcDNA5/FRT,and pBluescript+ plasmids were used for DNA cloning 
and amplification. pGEX-6p1, pET28a+, and pMAL-c2x plasmids were used for protein 
purification. PL253, PL451, and PL452 plasmids were used for BAC recombineering and 
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Table 2. Mammalian and bacterial expression vectors 
Vectore Provider 
pcDNA3.1 Invitrogen, Karlsruhe, Germany 
pcDNA5/FRT Invitrogen, Karlsruhe, Germany 
pGEX-6p1 GE Healthcare, Freiburg, Germany 
pET28a+ Novagen, Darmstadt, Germany 
pMAL-c2x NEB Biolab, Ipswich, USA 
PL253* Frederick National lab, Frederick, USA 
PL451* Frederick National lab, Frederick, USA 
PL452* Frederick National lab, Frederick, USA 
pBluescript+ Invitrogen, Karlsruhe, Germany 
* Kindly given by Prof. Ahmed Mansouri, Goettingen, Germany 
  
2.3.e.II. Oligonucleotides 
Table 3 presents a list and the sequence of oligonucleotides used for all PCR cloning. 
Oligonucleotides used for sequencing of the constructs and the whole genome are listed 
in Table 4. (F) refers to forward primer and (R) refers to reverse primer. 
 
Table 3. Oligonucleotides for cloning 
Name Direction Sequence 5'-3' Restriction site 
for 
pGEX-DLK NLS F AAGCCCCGGGGTTCCACAGAACACAAG SmaI 
R AATCTCGAGCTTCACCACATCGTC XhoI 
pET-DLK NLS F AAGGGATCCTCCACAGAACACAAG BamHI 
R AAGTGTCGACCTTCACCACATCGTC SalI 
pMAL-DLK NLS F AAGGGATCCTCCACAGAACACAAG BamHI 
R AAGTGTCGACCTTCACCACATCGTC SalI 
pMAL-KNLSLZ F AAGGGATCCTCCACAGAACACAAG BamHI 
R AAGTGTCGACGTTTCCATGTAGGAGG SalI 
PGK-DLK NLS2 F CGAGCTAGCATAGGGCGAAT NheI 
R CCCATGTCGACATCAAGCTT HindIII 
5' Southernblot  
probe 
F CGTAGAATTCTACGGGCAGCAAAT EcoRI 
R TATTGGATCCGCTGTCATAGCCTA BamHI 
3' Southernblot 
probe 
F CCGCGAATTCATGTAATTTTAACAATAC EcoRI 
R CGAAGGATCCGGTATTAAGCCAAACA BamHI 
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Gap-repair A F ATAAGCGGCCGCAGCTAATGGCACCTT NotI 
Gap-repair B R GTCAAGCTTCTAATGGTTGCTGGG HindIII 
Gap-repair C F ATAAGCGGCCGCCTGTAGGTAGGAGG NotI 
Gap-repair D R GTCGAATTCAGATCTCAAGTGCTCTACAA
AA 
EcoRI,BglII 
Gap-repair E F ATAGGATCCGCTAGGATGTGTAAAACC BamHI 
Gap-repair F R GTCGTCGACAGATCCCTGTAAGAACA SalI 
Gap-repair G F ATAAGCGGCCGCAAGGTGGATTAGAA NotI 
Gap-repair H R GTCGAATTCAGCACTTGAGAGGCAGAG EcoRI 
Gap-repair I F ATAGGATCCGGAATTAAAGGCATGTGCC BamHI 
Gap-repair J R GTCGTCGACGAACCTGTTACTGACATT SalI 
Gap-repair Y F GTCAAGCTTTCCTGTTTCTCTGCCCAAAC HindIII 
Gap-repair Z R TCTACTAGTTGTAGAGCAGCTGGTGCATT SpeI 
 
Table 4. Oligonucloetides for sequencing 
Name Direction Sequence 5'-3' 
pET-DLK NLS F GCTTTGTTAGCAGCCGGATCT 
R CAGCCATATGGCTAGCATGA 
pMAL-DLK NLS F TTCGAGCTCGAACAACAACA 
R TGCTGCAAGGCGATTAAGTT 
hIP-DLK NLS F CCATCAAGCAGGTCTGTTCCAA 
R GCACCTCATATAGCTGTCCT 
PGK-DLK NLS F CGTCTCACTAGTCTCGTGCAGAT 
R GGCACAACATCTCGAAGTACAC 
BAC recombineering 











Second loxP inserted into the F GGCTTGGAAGACACTATGT 
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targeting vector R CATCGCATTGTCTGAGTAGG 
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2.3.f. Antibodies 
All primary and secondary antibodies used in the present study are listed in Table 5. 
Table 5. Primary and secondary antibodies. 
Name Source Application Dilution Provider 
DLK rabbit Immunoblot 1:2,500 Holzman et al,. 1994 
phospho-DLK rabbit Immunoblot 1:1,000 This group 
Cleaved caspase3 rabbit Immunoblot 1:1,000 Cell signalling, 
Frankfurt M, Germany 
anti-His mouse Immunoblot 1:5,000 Sigma-Aldrich, Seelze, 
Germany 
GAPDH mouse Immunoblot 1:5,000 Santa Cruz, 
Heidelberg, Germany 
FLAG M2 mouse Immunocytochemistry 1:200 Sigma-Aldrich, Seelze, 
Germany 
Rabbit IgG-HRP* donkey Immunoblot 1:10,000 GE Healthcare, 
Freiburg, Germany 
Mouse IgG-HRP* sheep Immunoblot 1:10,000 GE Healthcare, 
Freiburg, Germany 
Rabbit IgG-Alexa®* goat Immunocytochemistry 1:50 Eugene, Oregon, USA 
anti-MBP mouse Immunoblot 1:5,000 NEB Biolabs, Ipswich, 
USA 
Tubulin rabbit Immunoblot 1:1,000 Cell signalling, 
Frankfurt M, Germany 
* Secondary antibodies 
 anti-DLK antibody detects the C-terminus of DLK protein. phospho-DLK antibody 
detects the phospho-serine 302 residue in DLK protein. Cleaved caspase3 antibody 
detects two bands of 17 and 19 kd of caspase3 peptide cleaved adjacent to Asp 175. anti-
His antibody detects the 6xHis box tagged to the proteins of interest. GAPDH antibody 
detects the full-length of human glutaraldehyde-3-phosphate dehydrogenase between 
amino acids 1-335.  
 FLAG M2 antibody detects the Flag epitope (DYKDDDDK) which is inserted 
between amino acids 1 and 2 in the proteins of interest.  
 Rabbit IgG-HRP and mouse IgG-HRP are labelled with horseradish peroxidase 
and were used as secondary antibodies in immunoblot experiments. 
 Rabbit IgG-Alexa® is labelled with AlexaFlour®488 and was used as secondary 
antibody in immunocytochemistry experiments. 
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2.3.g. Enzymes and Markers 
2.3.g.I. Restriction endonucleases 
Endonuclease restriction enzymes used in the present study are listed in Table 6. The 
enzymes were used in combination with appropriate buffer according to the instruction of 
manufacturer.  
 
Table 6. Restriction endonucleases 
Name Recognition site Provider 
BamHI 5'-G|GATCC-3' Fermentas, St. Leon-Rot, Germany 
DrdI 5'-GACNNNN|NNGTC-3' Fermentas, St. Leon-Rot, Germany 
EcoRI 5'-G|AATTC-3' Fermentas, St. Leon-Rot, Germany 
HincII 5'-GTY|RAC-3' NEB Biolabs, Ipswich, USA 
HindIII 5'-A|AGCTT-3' Fermentas, St. Leon-Rot, Germany 
NheI 5'-G|CTAGC-3' NEB Biolabs, Ipswich, USA 
NotI 5'-GC|GGCCGC-3' NEB Biolabs, Ipswich, USA 
SalI 5'-G|TCGAC-3' Fermentas, St. Leon-Rot, Germany 
SmaI 5'-CCC|GGG-3' Fermentas, St. Leon-Rot, Germany 
SpeI 5'-A|CTAGT-3' NEB Biolabs, Ipswich, USA 
XcmI 5'-CCANNNNN|NNNNTGG NEB Biolabs, Ipswich, USA 
XhoI 5'-C|TCGAG-3' Fermentas, St. Leon-Rot, Germany 
      
 
 
2.3.g.II. Modifying enzymes 
Modifying enzymes listed in Table 7 were used in combination with appropriate buffers 
according to the instruction of manufacturer. 
Table 7. Modifying enzymes 
Name Concentration            Provider 
CiAP (calf intestine alkaline phosphatase) 1U/µl Fermentas, St. Leon-Rot, Germany 
Lysozyme 4,700U/mg Sigma-Aldrich, Seelze, Germany 
Pfu DNA polymerase 2.5U/µl Fermentas, St. Leon-Rot, Germany 
Prime-STAR DNA polymerase 2.5U/µl Takara, St-Germain-en-Laye, France 
RNase A  Applichem, Darmstadt, Germany 
T4 DNA ligase 1U/µl Fermentas, St. Leon-Rot, Germany 
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 2.3.g.III. Molecular weight markers 
Markers and ladders were provided by Fermentas Life Sciences (St. Leon-Rot, Germany). 
PFG (pulsed-field gel) markers are from NEB Biolabs. 
 
DNA-ladders:  
GeneRuler™ 100bp DNA Ladder  
GeneRuler™ 100bp Plus DNA Ladder  
GeneRuler™ 1kb DNA Ladder  
GeneRuler™ 1kb plus DNA Ladder  
Mid Range PFG Marker 
Low Range PFG Marker 
Protein ladder:  
PageRuler™ Prestained Protein Ladder 
 
 
2.4. DNA oriented experiments 
2.4.a. Polymerase Chain Reaction (PCR) 
 PCR was used to amplify DNA in vitro. In this reaction a designed fragment of 
DNA is separated to single strand DNA by heating up to 95°C. Annealing of specific 
primer pairs occurs at the melting temperature of the primers. A thermostable DNA 
polymerase starts the elongation of the fragment from the annealed primers at 72°C. The 
time of elongation is dependent on the type of polymerase and the length of the fragment. 
The cycle is repeated up to 35 times. An overview of the reaction is shown below. 
a typical PCR reagents: 
DNA Template Genomic DNA (1-10 ng), plasmid DNA (10-50 ng) 
dNTPs 200 µM 
Forward primer 30 pmol 
Reverse primer 30 pmol 
Reaction buffer+Mg++ 1x 
Polymerase 1 U 
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a typical PCR setup:               
Initial denaturation 3 min at 95°C 
Cyclic denaturation 20sec at 95°C 
Primer annealing 20sec at 5°C lower than the melting 
temperature of the primers 
Elongation Time depended on polymerase and the 
length of the fragment, at 72°C 
Final elongation 7 min at 72°C 
 
dNTP mix was purchased from Fermentas as 10 mM stock solution. Primers were 
synthesized by MWG operon.  
The PCR product was subjected to horizontal electrophoresis on an agarose gel and 
purified. 
 
2.4.b. Agarose gel electrophoresis 
 Agarose gel electrophoresis was used for separation of DNA fragments. The size 
of the fragment determines the percentage of the agarose gel. The relation of these two 
factors is as follows: 
 
Percentage of agarose DNA fragment 
0.3 % 5–60 kb 
0.6 % 1-20 kb 
0.7 % 0.8-10 kb 
0.9 % 0.5-7 kb 
1.2 % 0.4-6 kb 
1.5 % 0.2-4 kb 
2.0 % 0.1-3 kb 
    (Sambrook, Fritsch et al. 1989) 
 
 Because of the difficult handling of the lower percentage gels (0.3.0.6%), 
preparation of a bed gel in higher percentage (1%) is recommended. Agarose was melted 
in TAE-buffer and cooled down to 60°C. Ethidiumbromide (5% v/v) was added and mixed 
well. The gel was casted and solidified at room temperature. The gel was placed in a 
running chamber and covered by TAE-buffer. DNA samples were supplemented with 6x 
loading dye (Fermentas) and loaded into the slots. 5µl of the appropriate DNA ladder were 
loaded beside the samples. A constant electric field (90V) was applied. When the loading 
35 
cycles 
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dye was almost at the end of the gel the electric field was stopped and the separation of 
the fragments was observed at UV-light of 366 nm. Other analysis and photography was 
performed by Bio Imaging System device and software.  
 
TAE-buffer 1x 1 l 
Tris 40 mM 4.84 g 
EDTA 1   mM 2 ml of 0.5 M stock 
Acetic acid 20 mM 1.14 ml 
 
 
2.4.c. DNA purification from agarose gel 
 Easy Pure® purification kit was used for DNA extraction from agarose gel. The 
desired band of DNA was cut out of the gel and melted at 55°C in 3 volume of the salt 
solution. Silica beads (5µl + 1 µl/µg of DNA) were added and mixed well by pipeting. After 
5 min of incubation at room temperature the beads were pelleted and washed 2 times with 
washing solution. The pellet was dried and DNA was eluted with 20 µl of ddH2O by 1 min 
centrifugation using a table centrifuge at high speed. All steps were done according to the 
instruction of the manufacturer.  
 
2.4.d. Restriction digest 
 Sufficient amounts of plasmid DNA or PCR product were mixed with ddH2O to a 
final volume of 50 µl. The corresponding buffer was added in a 1x dilution. The mixture 
was supplemented with 1U of restriction enzyme per µg of DNA. Digestion was carried out 
for 1-2 hrs for plasmid DNA and overnight for PCR products at 37°C. An exception in 
temperature should be considered for some enzymes. The samples were gel 
electrophoresed and gel purified as described above. 
 
2.4.e. DNA ligation 
 T4 DNA ligase facilitates the joining of DNA strands by catalyzing the formation of 
a phosphodiester bond. One important point to have a successful ligation is to take a 
proper ratio of vector and insert. 0.03 pmol of vector and 0.1-0.3 pmol of insert is a good 
ratio. The molecular weight of DNA can be measured by molecular weight calculators or 
conventionally by this equation:  
                                                   MW (g/mol)= DNA bp × 608 
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According to this formula, a DNA fragment of 1kb has a molecular weight of 60.8 g/mol. 
1µg of this fragment is equivalent to 1.65 pmol. The final calculation was corrected to the 
concentration of DNA which had been measured by Nanodrop. 
 The optimum temperature for T4 ligase activity is 25°C, with high temperature 
increase the chance of the homologous pairing of the sticky ends and the hydrogen 
bonding decreases. The optimum temperature for the ligation of 4 nucleotides overhang is 
between 12-16°C. 
 Regarding these rules, the fragments were mixed with ddH2O in a total volume of 
20 µl. 1x final concentration of ligation buffer was added and the mixture was 
supplemented with 1U of T4 DNA ligase and mixed well. The reaction was completed 
overnight at 16°C. The ligated DNA was amplified by transforming competent bacteria. 
 
2.4.f. Bacterial transformation 
2.4.f.I. Chemically competent E.coli  
The bacteria were thawed on ice. 100 ng of plasmid DNA or 3 µl of ligated DNA were 
added to 30 µl of bacteria and immediately kept on ice for 30 min. Heat shock was applied 
by 90 sec incubation at 42°C, followed by 2 min incubation on ice. 500 µl of LB medium 
without antibiotic were added to the bacteria and incubated for 1hr at 37°C, 350 rpm in a 
thermomixer. 100 µl of the transformed bacteria was plated on a LB-agar plate containing 
the appropriate antibiotic and incubated overnight at 37°C. 
 
2.4.f.II. Electro-competent E.Coli 
To prepare electro-competent bacteria, chemically competent bacteria were cultured in 
10ml LB medium without antibiotic, overnight at 37°C, 220rpm. Next day, 1 L of LB 
medium was inoculated with the overnight cultured bacteria, grown until the OD600 (optical 
density at 600 nm) reached 0.35-0.4, put immediately on ice and chilled for 30 min. The 
cells were pelleted using the already chilled centrifuge and washed 3-5 times with ice-cold 
ddH2O. The white pellet was re-suspended in in 2 ml of ice-cold 10% glycerol. The final 
OD600 of the resuspended cells should be approximately 200 - 250. The aliquots were 
stored at -80°C. (Department of Molecular & Cell Biology, University of California, 
Berkeley).  
 The freshly prepared bacteria or thawed aliquots on ice were added to 2µl of 
ligated DNA or 10ng purified plasmid and mixed by tapping at the tube. The mixture was 
transferred to a electroporation cuvette and the electroporation was performed using the 
Micropulser electroporator. 1ml LB medium without antibiotic was added to transformed 
bacteria and incubated for 1hr at 37°C, 350 rpm in a thermomixer. 100µl of the 
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transformed bacteria was plated on a LB-agar plate containing appropriate antibiotic and 
incubated overnight at 37°C. 
 
2.4.g. Mini preparation       
 High pure miniprep kits were used to extract plasmid DNA from bacteria. To 
screen the accuracy of the cloning conventional mini preparation (Sambrook, Fritsch et al. 
1989) was employed as described below. 
 
Buffer M1     100 ml       
Tris/HCl pH 8.0  25 mM  2.5 ml of 1 M Tris/HCl pH 8.0 stock solution 
Glucose   50 mM  10 ml of 0.5 M glucose stock solution 
EDTA pH 8.0   10 mM  2 ml of 0.5 M EDTA pH 8.0 stock solution 
add fresh before use: 
Lysozyme     2 mg / 1 ml buffer M1 
 
Buffer M2     5 ml       
NaOH    0.2 N  1 ml 1 N NaOH stock solution 
SDS    1%  500 µl 10%-SDS stock solution  
H2O sterile     3.5 ml 
 
Buffer M3     20 ml       
Na acetate pH 4.8  3 M  8.165 g / 20 ml 
  
The colony of interest was inoculated in 3 ml LB medium and incubated overnight at 37°C, 
200rpm in a bacterial shaker. Next day, 1.5 ml of the overnight cultured cells were 
transferred into a 2 ml-eppendorf tube and pelleted at 6000 rpm using a table centrifuge 
for 2 min. The pellet was re-suspended in 150 µl of buffer M1 and kept on ice for 10 min. 
200 µl of buffer M2 were added quickly and mixed by inversion (no vortexing) and kept on 
ice for 5 min. To stop the lysis, 150µl of buffer M3 were added and mixed by inverting the 
tube. After 10 min centrifugation at 14000 rpm, the supernatant was transferred into a new 
1.5 ml eppendorf tube. To extract DNA in aqueous phase 200µl of phenol and 200µl of 
(24 chloroform-1 isoamylalcohol) mixture was added to the tube and mixed by vortexing. 5 
min centrifugation at 14000 rpm is enough to separate the aqueous phase containing 
DNA from the lower organic phase (phenol) containing protein. The upper (aqueous) 
phase was transferred into new tube. 1/10 volume of buffer M3 was added and mixed. 2 
volume of ice-cold 99% ethanol was added and mixed well. The sample was kept in -20°C 
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for 15 min and centrifuged for 30 min at 14000 rpm, 4°C. Supernatant was discarded 
carefully, 500 µl of 70% ethanol was added and centrifuged for 5 min at 14000 rpm, 4°C. 
Supernatant was discarded and the pellet was dried at 37°C for 10 min. Pellet was solved 
in 21 µl of RNase A (0.1mg/ml) for 30 min at 37°C. The concentration of DNA was 
measured by nanodrop. 
 
2.4.h. Maxi preparation 
 To amplify large scale of plasmid DNA, High pure maxiprep kits were used beside 
the conventional maxi preparation (Sambrook, Fritsch et al. 1989) as described below.  
 
STE buffer  100 mL  
Tris/HCl pH 8.0  50 mM  5 mL of 1 M stock  
Saccharose  25% (w/v)  25 g  
EDTA pH 8.0  1 mM  0.2 mL of 0.5 M stock  
   
Triton-mix  100 mL  
Tris/HCl pH 8.0  50 mM  5 mL of 1 M stock  
Triton X100  0.1% (v/v)  0.1 mL  
EDTA pH 8.0  60 mM  12 mL of 0.5 M stock  
 
PEG solution  100 mL  
PEG 6000  30 g  
NaCl  1.5 M  30 mL of 5 M stock  
 
TNE buffer  
 
100 mL  
Tris/HCl pH 8.0  10 mM  1 mL of 1 M stock  
NaCl  10 mM  0.2 mL of 5 M stock  
EDTA pH 8.0  1 mM  0.2 mL of 0.5 M stock  
   
TE buffer  1 L  
Tris/HCl pH 8.0  10 mM  10 mL of 1 M stock  
EDTA pH 8.0  1 mM  2 mL of 0.5 M stock  
All buffers were stored at 4°C. 
A single colony was inoculated in 30 ml LB medium with the appropriate antibiotic and 
cultured overnight at 37°C, 225 rpm in a bacterial shaker.  
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Next day, the overnight culture was transferred into 1 L LB medium with the appropriate 
antibiotic and grown up at 37°C, 225 rpm to reach the OD600 of 0.4 - 0.8. 200 mg of 
chloramphenicol were solved in ethanol, added to the culture, and the incubation was 
continued overnight.  
The culture was pelleted in four 250 ml-centrifuge tubes at 4000 rpm for 15 min. Each 
pellet was re-suspended in 11.25 ml of ice-cold STE buffer and each 2 tubes were pooled 
in a one 50 ml centrifuge tube. 1.5 ml of lysozyme (60µg/ml of STE) was added to the re-
suspended cells and incubated on ice for 20 min. 1.8 ml of 0.5 M EDTA (pH. 8) was 
added and incubated in ice for 5 min. 14.4 ml of Triton-mix was added and incubated in 
ice for 30 min. In this step it’s important to shake the mixture every 5 minutes. After 1 hour 
centrifugation at 16000 rpm, 4°C, the supernatant was transferred into a 250 ml centrifuge 
tube. 40 ml of 30% PEG was added and incubated on ice for 1 hour. 10 min of 
centrifugation at 10000 rpm, 4°C, was applied, the supernatant was discarded and the 
pellet was dried using N2 flow. The dried pellet was re-suspended in 10 ml of TNE buffer.   
10.9 g CsCl plus 150 µl of 10 mg/ml ethidiumbromide were added to the solution and then 
transferred into ultracentrifuge Quick Seal tubes using a syringe and needle. The tubes 
were weighted. The difference between the filled tubes should not be more than 0.05g. 
The tubes were heat-sealed. After 20 hrs of ultracentrifugation at 60000 rpm, the red color 
band containing plasmid DNA was isolated and transferred to a 15ml tube.  
Ethidiumbromide was extracted from the DNA by washing with the same volume of 
isoamylalcohol, until a colorless solution is obtained. During the washing plasmid DNA is 
always in the lower phase.  
To remove CsCl from DNA, the sample was dialyzed twice, 12 hrs against TE buffer using 
a ¼ diameter dialysis tube at 4°C.  
 
2.4.i. Measurement of DNA 
After the dialysis was completed, the purity and the concentration of plasmid DNA were 
measured by a Nanodrop or other spectrophotometer. The OD260/OD280 ratio between 
1.8 and 2 shows a good purity of DNA, but a ratio less than 1.8 represents bad purity of 
the extracted plasmid. The concentration of DNA can be calculated as follows: 
 
                   
                      
    
   (µg/µl)    
 
The absorbance at 260 nm in a 1 cm quartz cuvette of a 50 µg/ml solution of double 
stranded DNA is equal to 1, since the number 50 is used as a factor for the DNA 
concentration calculation from the measured OD260 in the above mentioned equation. 
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2.4.j. Sequencing 
 Sequencing service of Seqlab and MWG operon was used to sequence the 
generated constructs. The chain-termination method (Sanger, Nicklen et al. 1977) was 
used for sequencing the genomic DNA. In this method the fragments are amplified by a 
PCR reaction using labeled dideoxynucleotides which are involved in Big Dye® 
Terminator v1.1 sequencing kit.  
The reaction was prepared as follows: 
DNA 300 ng 
Primer 10 pmol 
BigDye® mix 1.8 µl 
ddH2O ad 20 µl 
 
The PCR program was set up by following steps: 
Initial denaturation 2 min at 94°C 
Cyclic denaturation 15 sec at 96°C 
Primer annealing 15 sec at 55°C 
Elongation 4 min at 60°C 
Final elongation 7 min at 72°C 
 
 The 96-well Millipore plate was filled by Sephadex resin and washed with ddH2O. 
The PCR products were equalized to a final volume of 40µl by ddH2O and loaded on  
prepared Sephadex. The samples were purified by 5 min centrifugation at 2000 rpm. The 
purified samples were applied to a capillary electrophoresis device and the results were 
analyzes using the ABI PRISM 3100 Genetic Analyzer.  
 
2.4.k. Generation of targeting vector for DLK  
In this experiment bMQ 317c09 has been used from bMQ BAC (Bacterial Artificial 
Chromosome) library. The vector carries sequences from 102.269.880-102.418.975 + 
strand on chromosome 15 (MAP3K12) of mouse SV129, inserted in BamHI restriction 
site. 
  
2.4.k.I. Digestion pattern of bMQ 317c09 
To check the accuracy of the made construct, the vector was cut by NotI overnight and 
run on agarose gel using a pulse field running system. 
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Time: 18 hrs Final switch time (Sf): 25 
Voltage: 6 V/cm Angel: 120° 
Initial switch time (Si): 1   
0.5x TBE buffer used for making 1% agarose gel and for electrophoresis. PFG (pulsed-
field gel) middle range and low range markers from NEB were used as DNA ladder. 
 
2.4.k.II. Gap-repair protocol 
The gap-repair protocol describes how to generate a targeting vector for the generation of 
conditional cko (knock-out)-mouse model (Liu, Jenkins et al. 2003). A schematic figure of 
this protocol is depicted in Fig. 2.1 and Fig. 2.2.   
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Figure 2. 1 Gap repair protocol for DNA recombineering. The DNA fragment which needs to be 
modified is subcloned from BAC plasmid to the targeting vector recruiting homologous 
recombination strategy. The neo cassette which is flanked by two loxP sites is introduced into the 









Figure 2. 2 Gap repair protocol for DNA recombineering. The neo cassette is excised by Cre-
recombinase which left one of the two loxP sites on the vector backbone. The second loxP site is 
introduced through homologous recombination using a neo cassette flanked by two FRT (flippase 
recognition target) sequences, allowing the removal of the neo cassette by flippase (flpe) without 
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As illustrated, generation of a conditional cko-targeting vector consists of several steps: 
1-   Preparation of a restriction digest map 
2- Generation of homology arms 
3- Generation of retrieval plasmid 
4- Retrieval of DNA from BAC into retrieval plasmid 
5- Generation of mini-targeting vectors 
6- Introduction of the first loxP site 
7- Removal of the first neo cassette 
8- Introduction of the second loxP site 
 
2.4.k.II.1- Generation of homology arms and gap-repair plasmid 
Two regions of about 500 bp of the BAC DNA were amplified using two sets of primers (A 
and B, and Y and Z). To apply a directional cloning of the PCR product into the 
pBluescript plasmid (pBSK+) multiple cloning site, restriction sites of different enzymes 
were included in the primers as follows: HindIII in primers A and Y, NotI in primer B and 
SpeI in primer Z. The PCR products were purified using Biozym easy pure kit and 
digested with either NotI and HindIII or HindIII and SpeI. The digested fragments were 
purified again and ligated into the NotI and SpeI linearized PL253 plasmid. PL253 is a 
pBluescript-drived plasmid for retrieval of DNA from BAC. This plasmid contains a Mc1-
driven thymidine kinase (TK) cassette for negative selection in ES cells. 2µl of ligated mix 
were electroporated into Top10 electro-competent cells. The positive colonies were 
selected by ampicillin resistance.  
 
2.4.k.II.2- Retrieval of DNA from BAC 
SW102 bacteria are DH10B bacterial strain which have been transformed by the defective 
λ prophage. The λ prophage contains the Red family (exo, and bet), and gam genes 
which are involved in recombination process. The expression of these genes is 
temperature inducible (section 4.3.b). SW102 cells were inoculated in LB medium 
overnight at 30°C. The next day a dilution of 1 to 50 from the overnight culture was grown 
at 30°C to reach the OD600 of 0.6. The cells were pelleted by centrifugation at 6000 rpm 
for 2 minutes. The pellet was washed 4-5 times with ice cold MQ autoclaved water to 
make fresh electro-competent cells. After washing, the pellet was re-suspended in 200 µl 
of ice cold MQ autoclaved water.  
1 µl of BAC DNA was transferred into 40 µl of prepared SW102 cells by electroporation. 
The transformed cells were inoculated on a chloramphenicol agar plate (12.5 µg/ml 
chloramphenicol). DNA was extracted from positive colonies using miniprep protocol and 
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digested with NotI to compare with early digestion pattern (section 2.4.k.I). Colonies 
carrying the BAC were used for recombination experiment. 
 SW102 cells containing BAC was grownup overnight at 30°C. The next day a 
dilution of 1/50 was cultured in a total volume of 30 ml to reach the OD 600 of 0.6 (3-4 
hrs). 15 ml of the culture were incubated at exactly 42°C for 15 minutes (to induce the Red 
recombination functions), and the rest 15 ml at 32°C as control. The cells were made 
electro-competent by washing several times with ice cold MQ autoclaved water, as 
described before. 
Gap-repair plasmid which has AB and YZ homology arms was linearized with HindIII and 
purified from the gel. 1µl of linearized plasmid was transferred into 40µl of either induced 
or noninduced SW102 cells containing BAC DNA, by electroporation. 
Transformed cells were grown on an ampicillin agar plate at 30 °C overnight. DNA was 
extracted from the ampicillin resistant colonies, which carry the targeting plasmid, and 
digested with EcoRI to compare with the prepared map(Fig. 3.13.A). DNA of interest was 
kept for the next step. 
 
2.4.k.II.3- Generation of the first mini targeting vector 
This mini vector permits the insertion of the loxP site into the desired DNA sequences by 
homology recombination and neo positive selection. Two regions of homology arms, up 
and down to the stretch where loxP site will be introduced, were amplified using two sets 
of primers ( CD and EF) in which the NotI and EcoRI, BamHI and SalI recognition sites 
were included, respectively. The PCR products were digested by the appropriate enzymes 
and purified with Biozym easy pure kit. The loxP flanked neo cassette was cut out of 
PL452 plasmid with BamHI and EcoRI restriction enzymes and purified from the gel. 
pBSK+ plasmid was linearized with NotI and SalI and purified from the gel. The purified 
homology arms and the purified loxP flanked neo cassette were ligated into the linearized 
pBSK+ plasmid. The positive colonies were selected on kanamycin (15µg/ml) agar plate. 
DNA was extracted by miniprep and the accuracy was controlled by restriction digestion 
and sequencing. 
 
2.4.k.II.4- Introduction of the first loxP site 
The loxP flanked neo gene, together with the homology arms, was excised from pBSK+ by 
NotI and SalI digestion, and gel-purified.  
Red recombination functions were induced in SW102 cells by growing them at 42°C for 15 
min. The cells were made electro-competent as described before. 150ng of purified 
fragment co-electroporated along with 10 ng of purified gap-repaired subcloned DNA into 
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already induced electro-cmpetent cells. Transformants were selected on kanamycin 
plates. The restriction digestion patterns were used along with sequencing to ensure the 
accurate recombination.  
 
2.4.k.II.5- Excision of the first neo cassette 
A single colony of SW106 cells was cultured in 5 ml LB medium at 32 °C, overnight. Next 
day 1 ml of overnight culture was inoculated in 10 ml LB medium at 32°C for 3 hrs 
(OD600= 0.5). Cre expression was induced in SW106 cells by growing in arabinose-
containing media. 100µl of 10% arabinose added to the culture and incubated on bacterial 
shaker at 32°C for 1 hour. The cells were made electro-competent by washing several 
times (4-5 times) with ice cold MQ autoclaved water and transformed with gap-repaired 
plasmid containing loxP flanked neo cassette by electroporation. The electroporated cells 
were plated on either ampicillin (100µg/ml) or kanamycin (15µg/ml) plates. With a 
successful Cre-mediated recombination no colonies will grow on kanamycin plate. 
Colonies growing on ampicillin plate were checked for their kanamycin sensitivity by 
plating on kanamycin agar plate. Restriction digestion pattern was used besides 
sequencing to control that the neo cassette has been excised properly.  
  
2.4.k.II.6- Introduction of the second loxp site 
The FRT (flippase recognition target) flanked Neo+loxP fragment was cut out from PL451 
plasmid by BamHI and EcoRI and gel purified. The homologous arms GH and IJ were 
digested by NotI and EcoRI, and BamHI and SalI, respectively. The homologous arms 
and the Neo cassette were ligated into the pBSK+ vector which had been already 
linearized by NotI and SalI. The constructed vector was transferred into TOP10 cells by 
electroporation and the positive colonies were selected on Kanamycin agar plate. After 
DNA extraction from positive colonies, which carrying the neo cassette integrated into the 
targeting vector,  and sequencing the cloned fragment was cut out from mini vector by 
NotI and SalI restriction enzymes and gel purified.  
The purified fragment was co-electroporated with the targeting vector from the previous 
step into SW102 competent cells which had been induced before at 42°C for 15 min. The 
transformed colonies were selected on Kanamycin agar plate. DNA of the colonies was 
extracted and digested by EcoRI and the digestion pattern was compared to the prepared 
map (Fig. 3.19).  
Since pBluescript is a high-copy plasmid the cell might carry the targeted and 
nontargeted plasmids after recombination carried out. In this case both positive and 
negative digestion pattern is observed for the same extracted DNA. To overcome this 
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problem 1ng of the targeted vector was electroporated into TOP10 cells and the colonies 
were selected on Kanamycin agar plate. After digestion of the extracted DNA with EcoRI 
the positive clones can be distinguished from the negative ones by comparing to the 
prepared map. Sequencing proved the accuracy of the cloning.   
To functionally test the loxP and FRT sites in the targeting vector, the cko-targeting vector 
was transferred into arabinose-induced SW106 and SW105, respectively, by 
electropoation. SW106 cells have a Cre recombinase gene under the control of an 
arabinose-inducible promoter, whereas SW105 cells have Flpe recombinase under the 
control of an arabinose-inducible promoter. Cells were plated on ampicillin plates for the 
selection of the transformed cells which are expected to be ampicillin resistant. Plasmid 
DNA was prepared and digested with EcoRI to confirm the expected recombination. 
Sequencing was done to control the accuracy of the digestion pattern.    
  
2.5. Protein oriented experiments 
 2.5.a. Bradford assay 
  The Bradford assay was performed to measure the concentration of extracted 
proteins. The Dye Reagent containing the Coomassie Brilliant Blue G-250 has different 
colours in different pH. At pH less than 1 the colour is red with absorption maximally at 
470 nm. The colour changes to green when the pH is 1≥<2 with maximum absorption at 
620 nm, and the dye is bright blue when the pH is above 2 with maximum absorption at 
595 nm (Chial HJ 1993). Binding to proteins, changes the colour of the reagent to blue. 
The intensity of the blue colour correlates with the amount of proteins in solution 
(Bradford, 1976). The reagent was diluted 1:5 in H2O. Different concentrations of BSA 
were used to generate a standard curve ranging from 0.1 µg/ml to 30 µg/ml in coomassie 
reagent. The spectrophotometer measures the OD595 of different concentrations and 
generates a standard curve. (Biometer, Eppendorf). 1µl of protein sample was added to 1 
ml of diluted reagent, mixed well and kept at room temperature for 5 min. The optical 
density of the samples was measured at 595 nm. The spectrophotometer calculates the 
concentration of the protein according to the previously generated standard curve. When 
the OD595 of the sample is in the range of the standard curve the corresponding 
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2.5.b. SDS-PAGE electrophoresis 
 Buffers used for SDS-PAGE electrophoresis are listed below. 
Stacking gel buffer  200 mL  




0.4% (w/v)  8 mL of 10% SDS  
Separating gel buffer  200 mL  
Tris/HCl pH 8.8  1.5 M  36.342 g  
SDS  0.4% (w/v)  8 mL of 10% SDS  
  
 
Running buffer  1 L  
Tris  25 mM  3.03 g  




0.1% (w/v)  10 mL of 10% SDS  
Laemmli-loading buffer  2x  100 mL  
Tris/HCl pH 6.8  160 mM  16 mL of 1 M stock  
SDS  4 % (w/v)  4 g  
Glycerol  10 % (v/v)  10 mL 99.5% Glycerol  
Bromophenolblue  0.05 % (w/v)  50 mg  
β-Mercaptoethanol  10 % (v/v)  10 mL  
Laemmli-loading buffer was stored in aliquots at -20°C 
 The gel caster components, including glass plates with 1.0 mm spacer and short 
glass plates were set up according to the manufacturer’s instructions (Bio-Rad). 
Separating gel in the desired concentration of acrylamide-mix were prepared and poured 
into the set plate.  






Ingredients for a sample stacking and separating gel: 
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Stacking gel 4% 5 ml  Separating gel 10% 8 ml 
ddH2O 3 ml  ddH2O 3.2 ml 
Stacking gel buffer 1.25 ml  Separating gel buffer 2 ml 
Acrylamide-mix 670 µl  Acrylamide-mix 2.67 ml 
10% APS 50 µl  10% APS 80 µl 
TEMED 5 µl  TEMED 8 µl 
 
 TEMED was added when the solution was mixed very well and the gel was poured 
immediately. 5 ml of prepared separating gel mixture was poured into the set plate. 200 µl 
of Isopropanol were added at the top of the gel to make the surface even. After 
polymerizing, isopropanol was carefully removed. The stacking gel was poured into the 
plate, the appropriate comb was inserted immediately, and the gel was left at room 
temperature to polymerize (30-60min). 
 The gel was fixed in the running chamber according to the instruction of the 
manufacturer, and the chamber was filled up with the running buffer. The comb was 
removed carefully and the slots were washed with the running buffer using a micropipette 
and long tip. 
 The samples were supplemented with the same volume of 2x laemmli-loading 
buffer and boiled for 10 min at 95°C. The droplets were collected from the wall by a short 
spinning down using the table centrifuge. The same amount of protein was loaded into 
each slot of the gel. 5 µl of prestained PageRuler was loaded as molecular weight marker. 
An electricity field of 80V was applied to start the electrophoresis. When the loading dye 
passed through the border between the stacking gel and separating gel, the electrical field 
was raised up to 110V. The run was stopped when the loading dye left the bottom of the 
gel. The gel was segregated from the unit and transferred to a new dish containing 
ddH2O.   
 
2.5.c. Coomassie blue staining 
 Proteins can be detected on SDS-PAGE by staining with coomassie brilliant blue. 
The staining and destaining solutions were prepared as follows: 
 
Staining solution  1 L  
Coomassie brilliant blue  0.25 % (w/v)  2.5 g  
Methanol  40 % (v/v)  400 mL  
Acetic acid 10 % (v/v)  100 mL  
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Destaining solution  1 L  
Isopropanol  25 % (v/v)  250 mL  
Acetic acid  10 % (v/v)  100 mL  
Methanol  10 % (v/v)  100 mL  
 Proteins were electrophoresed. The gel was washed with ddH2O for 10 min and 
transferred to the staining solution. After 20 min shaking on a rocking platform the staining 
solution was removed and the stained gel was washed first by ddH2O to wash out the 
remnants of the dye and then with destaining solution on a rocking platform. The 
destaining solution was changed repeatedly to decrease the washing time and gain a 
more transparent gel. The gel was dried in cellophane using a gel dryer according to the 
instruction of the manufacturer. 
   
2.5.d. Immunoblot 
 Immunoblot was used for qualitative and quantitative analysis of proteins using 
specific antibodies for the detection of specific proteins. Buffers and solutions used for 
immunoblotting are listed below. 
 
Transfer buffer 1x 2L 
Glycine 192 mM 28.8 g 
Tris base 25 mM 6.04 g 
Methanol 10%v/v 200 ml 
ddH2O  ad 2 L 
 
TBS-T  1 L 
Tween 0.1% (v/v) 1 ml 
TBS  ad 1 L 
 
Blocking solution  50 ml 
Milk powder 5% (w/v) 2.5 g 
TBS-T  ad 50 ml 
 
Antibody solution  10 ml 
Milk powder 1% (w/v) 100 mg 
TBS-T  ad 10 ml 
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Blocking and antibody solutions were prepared freshly before use. 
 After SDS-PAGE, the gel was washed with ddH2O for 5 min on a rocking platform, 
and then equilibrated to transfer buffer for 5 min on a rocking platform. Whatman paper 
and nitrocellulose membrane were soaked in the transfer buffer. A Wet/Tank blotting 
system was used to transfer proteins from the gel to the membrane. The blotting sandwich 
was packed in a way that the gel faced to the negative pole and the membrane faced to 
the positive pole (Fig. 2.3). Three layers of Whatman paper were placed on the sponge in 
the black side of the sandwich. The gel lay down on the paper and the membrane lay 
down on the gel. Three more layers of Whatman paper were put on the membrane and 
the sandwich was packed with another sponge. The package was placed in the chamber 
filled with transfer buffer. An ice box was used to cool the system down. An electricity 
current of 400 mA applied to run the transfer for 1hr.  
 The membrane was soaked in Ponceau solution for 15 min on a rocking platform 
to control a successful transfer. The membrane was destained by TBS-T and incubated 
with blocking solution for 1hr at room temperature on a rocking platform. The blocking 
solution was replaced by the antibody solution containing the primary antibody and 
incubated overnight on a rocking platform at 4°C. The next day the membrane was 
washed 3 times with TBS-T, 10 min each time and incubated with the antibody solution 
containing the secondary antibody for 1hr at room temperature. Afterward the membrane 




Figure 2. 3 The blotting package. The gel is faced to the negative pole and the membrane is 
faced to the positive pole. The electrical current from the negative pole to the positive pole in the 
blotting chamber facilitates the transfer of proteins from the gel to the membrane. 
 The Lumi-lightplus kit was used for immunodetection according to the instruction of 
the manufacturer. The detection was performed using a Chemi Genius or Versa doc 
imaging system. Quantity-one software was used for the evaluation of the optical density 
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2.5.e. Protein purification 
 Affinity chromatography was used for the purification of the proteins from the 
bacterial extract. In this method the protein is fused to an agent which has a specific 
binding substrate. Binding to the substrate pools out the fused protein from the solution, 
allowing the purification of the protein of interest. The chromatography column is filled with 
the chromatography resins which are covered by the specific substrate. By running the 
solution containing the proteins through the column, the fused proteins bind to the 
substrate and the rest of the proteins pass through the column. By adding a high 
concentration of the binding substrate, the proteins can be refine from the resins. In this 
study, three fusion systems were used for the purification of proteins. The GST (glutathion 
S-transferase)-fusion system with glutathion as binding substrate, the His-tagged protein 
system with imidazole as binding substrate, and the MBP (maltose binding protein)-fusion 
system with maltose as binding substrate.  
   
2.5.e.I. GST-fusion protein 
DLK NLS was subcloned into the multiple cloning site of the pGEX-6p1 vector, directed by 
restriction enzymes. The coding sequence of DLK NLS containing the amino acids 140-
285 was fused to GST. The expression of GST and the polypeptide fused to it is under the 
control of lac operon. In the absence of Lactose the lac repressors inhibit the expression. 
Lactose and similar molecules like IPTG (isopropyl-beta-D-thiogalactopyranoside) bind 
and inactivate the lac repressors and thereby inducing the expression of fusion protein on 
the expression vector. 
 
2.5.e.I.1- Screening  
The screening was performed to select the colonies in which the expression of the fused 
protein is well induced by IPTG for the large scale purification. DH5α chemically 
competent cells were transformed with the construct and plated on ampicillin agar plate. 7 
growing colonies were picked and inoculated in 2 ml of LB containing 50 µg/ml ampicillin, 
shaking overnight at 37°C in a bacterial incubator. Next day, 100 µl of the each culture 
were inoculated in 2 ml of the LB containing ampicillin and cultured for 1hr at 37°C, 220 
rpm. 
500 µl of each tube was saved as control and the rest was supplemented with 1mM IPTG 
to induce protein expression and cultured for another 2 hrs at 37°C, 220 rpm. 500 µl of 
induced cultures were transferred to 1.5 ml eppendorf tubes. All control and induced 
samples were pelleted by centrifugation at 6000 rpm for 2 min using a table centrifuge. 20 
µl of Laemmli-loading dye was added to each sample and boiled for 10 min at 95°C. The 
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samples were spun down and applied on a SDS-PAGE. The gel was stained with 
coomassie blue and the inducible samples were chosen for large scale purification. 
 
2.5.e.I.2- large scale purification 
10 ml of overnight culture of inducible sample was inoculated in 1 L of the LB containing 
ampicillin to reach the OD 600 of 0.6. In this state bacteria have a logarithmic growth, 
500µl of bacteria was kept as control and 238 mg IPTG (1 mM final concentration) was 
added to the rest to induce expression at 37°C for 3 hrs. 500 µl of induced bacteria was 
taken and the rest was harvested by 10 min centrifugation at 4000 rpm using a Beckmann 
J2.21 centrifuge. The pellet was re-suspended in 30 ml of extraction buffer and kept in -
80°C overnight. 
 Sufficient amounts of glutathione agarose beads were swollen overnight in 10 ml 
of PBS at 4°C. The next day, the beads were washed 3 times with 5 ml of the extraction 
buffer and finally a 50% slurry suspension of the beads in extraction buffer was prepared 
and kept on ice. 
 
Extraction buffer 50 ml 
PBS ad 50 ml 
DTT 1 mM 
PMSF 1 mM 
The extraction buffer was prepared freshly before use. 
 
Elution buffer Final concentration 10 ml 
Tris pH 8.0 50 mM 0.5 ml of 1 M stock 
Glutathione 10 mM 30.7 mg 
ddH2O  ad 10 ml 
The elution buffer was prepared freshly before use and the pH was adjusted to 7.4 
 
The sample was thawed on ice and the lysis was completed by 3 times sonication using 
Bandelin Sonopuls sonicator. The setting of the sonicator was as follows: 




To avoid the denaturation of the proteins the sample was kept in an ice-water-methanol 
bath during the sonication. The sonicated solution was pelleted by centrifugation at 4000 
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rpm for 30 min at 4°C. The supernatant was transferred into a 50 ml tube. 10 µl of the 
crude extract were kept for control. A tiny piece of the pellet was re-suspended in 50 µl 
extraction buffer and 10 µl of it was kept for control. 1 ml of the prepared GSH-agarose 
bead was added to the crude extract and incubated on an up and down rotator at 4°C for 
2hrs. The beads were spun down for 10 min at 1200 rpm. 10 µl of the supernatant was 
kept for control. The beads were washed 3 times with 5 ml of extraction buffer. The 
protein was sequentially eluted from the beads by 600 µl of elution buffer in a 2 ml-
eppendorf tube, shaking at 1000 rpm using a thermomixer for 10 min at room 
temperature. The eluted solution was collected by 1 min centrifugation at high speed 
using a table centrifuge.  
Elution fractions were assessed by mini-bradford assay and the highest concentration 
fractions were selected. The eluted protein was dialyzed 2 times against 1 L of the 
extraction buffer for 2 hrs at 4°C. 5 µl of the sample was taken for control and the rest was 
supplemented with 10% glycerol and kept at -80°C. The preserved samples for control 
from all steps were supplemented with laemmlie-loading dye applied to SDS-PAGE. 







Figure 2. 4 Coomassie staining of GST-fusion protein. The preserved samples for control 
during the purification steps were subjected to SDS-PAGE. The gel was stained with coomassie 
dye. The GST-fusion DLK NLS is presented at 43 kDa.  
 
2.5.e.II. His-tagged protein 
DLK NLS was subcloned into the multiple cloning site of the pET28a+ vector. The coding 
sequence of DLK NLS containing the amino acids 140-285 is fused to a poly-Histidine 
epitope box. The expression of the tagged protein is under the control of lac operon. The 
BL21 competent bacteria were transformed by the expression plasmid. The screening 
43 kDa 
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step was performed as described in section (2.5.e.I.1). The buffers used in this 
experiment are listed below. 
 
Lysis Buffer pH 7-8 1x 
Tris-HCl 50 mM 
Glycerol 5% 
NaCl 50 mM 
 
 
Binding buffer pH 7-8 1x 
Tris-HCl 20 mM 
NaCl 0.5 M 
Imidazole 5 mM 
 
Washing buffer pH 7-8 1x 
Tris-HCl 20 mM 
NaCl 0.5 M 
Imidazole 60 mM 
 
Elution buffer pH 7-8 1x 
Tris-HCl 20 mM 
NaCl 0.5 M 
Imidazole 1 M 
10 ml of the overnight culture of inducible sample was inoculated in 1 L  of the LB 
containing ampicillin and grown to an OD600 of 0.6. 500 µl of the bacteria were kept as 
control and 238 mg IPTG (1mM final concentration) were added to the rest to induce 
expression at 37°C for 3 hrs. 500 µl of induced bacteria was taken and the rest was 
harvested by 10 min centrifugation at 4000 rpm using a Beckmann J2.21 centrifuge. The 
pellet was re-suspended in 30 ml of lysis buffer and kept in -80°C overnight. The next day, 
the pellet was thawed on ice. 100 kU of lysozyme was added and incubated on a rocking 
platform for 20 min at room temperature. Sonication was performed as described in 
section (2.5.e.I.2). The sonicated solution was pelleted by centrifugation at 4000 rpm for 
30 min at 4°C. The supernatant was transferred into a 50 ml tube. 10 µl of the crude 
extract were kept for control. A tiny piece of the pellet was re-suspended in 50 µl of lysis 
buffer and 10 µl of it was kept for control. 
His Bind Resin was gently mixed and suspended. The 50% slurry resin is covered and 
charged by Ni2+ cations which bind to the His-tag epitope sequence. 1.5 ml of slurry 
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suspension was transferred into a 2 ml tube and washed 2 times with binding buffer. The 
resin was added to the crude extract and incubated on an overhead rotator at 4°C for 
2hrs. The beads were spun down for 10 min at 1200 rpm. 10 µl of the supernatant was 
kept for control. The beads were washed 3 times with 1 ml binding buffer and 3 times with 
1 ml washing buffer in a 2 ml-eppendorf tube. The protein was sequentially eluted from 
the beads by 600 µl of elution buffer in a 2 ml-eppendorf tube, shaking at 1000 rpm using 
a thermomixer for 10 min at room temperature. The eluted protein was collected by 1 min 
centrifugation at high speed using a table centrifuge.  
Elution fractions were assessed by mini-bradford assay and the highest concentration 
fractions were selected. The eluted protein was dialyzed 2 times against 1 L of PBS+1 
mM DTT for 2hrs at 4°C. 5 µl of the sample was taken for control and the rest was 
supplemented with 10% glycerol and kept at -80°C. The preserved samples for screening 
from all steps were supplemented with laemmlie-loading dye applied to SDS-PAGE. 







Figure 2. 5 Coomassie staining of His-tagged protein. The preserved samples for control during 
the purification steps were subjected to SDS-PAGE. The gel was stained with coomassie dye. The 
His-tagged DLK NLS is presented at 22 kDa. 
 
2.5.e.III. MBP-fusion protein 
DLK KNLSLZ was subcloned into the multiple cloning site of the pMAL-c2x vector. The 
coding sequence of DLK KNLSLZ containing the amino acids 140-517 is fused to MBP. 
The expression of the fusion protein is under the control of lac operon and is induced by 
IPTG. The K12Δ competent bacteria were transformed by the expression vector. All steps 
are similar to section (2.5.e.I), except: the column buffer was used instead of the 
22 kDa 
Materials and methods  
 
Page | 70  
 
extraction buffer, the elution buffer contained maltose instead of glutathion, dialysis was 
performed against the extraction buffer (2.5.e.I), and amylose resin was used instead of 
glutathion-agarose bead. The amylose resins are covered by amylose which has a 
binding affinity to MBP. The bond MBP-fusion proteins can be refined by maltose (Fig. 
2.6). 
 
Figure 2. 6 Schematic figure of affinity chromatography protein purification. The amylose 
resin is covered by amylose molecules which bind to MBP sequences. The MBP-fusion protein is 
refined from the cell extract solution by the binding affinity of MBP to amylose. The fusion protein is 
retained from the resin by adding a high concentration of maltose which binds competitively to 




Column buffer 1x 
Tris-HCl 20 mM 
NaCl 200 mM 
EDTA* 1 mM 
DTT* 1 mM 
PMSF* 1 mM 
* added freshly before use. 
 
Elution buffer 1x 
Column buffer 1x 
Maltose 10 mM 
 
 
2.5.f. Protein-protein interaction assay 
Protein-protein interaction assay was performed to investigate the interaction between 
DLK NLS wild-type and mutants and some of the import proteins. MBP-DLK KNLSLZ and 
His-tagged importins (α, β, and transportin) were used in this experiment (Fig. 2.7). 
 
resin 
MBP DLK NLS 















Materials and methods  
 






Figure 2. 7 Schematic figure for protein-protein interaction. The MBP-fusion proteins are 
immobilized to amylose resins. The interaction is performed between the MBP-fusion proteins and 
the His-tagged proteins, and can be detected by immunoblot using an anti-His antibody.  
 
 
TPB buffer is a modified buffer for this experiment. 
TPB buffer 1x 
KoAc 110 mM 
HEPES pH 7.4 20 mM 
MgoAc 2 mM 
DTT 1 mM 
Protease inhibitor 1x 
 
Blocking buffer 1x 
TPB buffer 1x 
Fatty acid free BSA 10 mg/ml 
The buffers were prepared freshly and kept on ice. 
 500 µl of the slurry amylose resin were washed 3 times with TPB buffer and 
incubated with blocking buffer for 30 min on an overhead rotator at 4°C. 
 The resin was split into three 2 ml eppendorf tubes. 15 µg of each MBP fused 
proteins (DLK KNLSLZ wt, 1, and 2 mutants) was added to the tubes and labeled. The 
tubes were incubated for1hr at 4°C on a rotator. Meanwhile the importins were prepared 





  DLK KNLSLZ wt DLK KNLSLZ1 DLK KNLSLZ2 
Importin α 2 µg 2 µg 2 µg 
Importin β 2 µg 2 µg 2 µg 
Transportin 2 µg 2 µg 2 µg 




MBP NLS importin 6x His 
anti-His 
antibody 
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The resin was washed 3 times with 1 ml blocking buffer, spun down at 500 rpm for 1 min 
using a table centrifuge, and re-suspended in 200 µl blocking buffer. 20 µl of resin was 
added to each labeled tube containing importins and incubated for 2 hrs at 4°C on a 
rotator. 
 The resins were washed 3 times with 1 ml TPB buffer and spun down at 500 rpm 
for 1 min. The supernatant was discarded; 20 µl of laemmli-loading dye was added and 
boiled at 95°C for 5 min. The samples were analyzed by SDS-PAGE and immunoblotting 
using an anti-His antibody. 5% of the importin input (5% of 2 µg=0.1 µg) was loaded 
beside the samples to observe the interaction efficiency.   
 
2.5.g. Preparation of cell lysates for immunoblotting 
The lysis buffer used in this method was as follows: 
Lysis buffer 1x 
HEPES pH 7.5 50 mM 
NaCl 150 mM 
MgCl2 1.5 mM 
EGTA 1 mM 
Triton X-100 1% 
Protease and phosphotase inhibitors were added freshly before use. 
 The medium was removed and the cells were washed with PBS and kept on ice. 
The cells were detached from the dish using a cell scraper and collected in 50-150 µl of 
lysis buffer (depending on the number of cells). Lysis was completed by three freeze-thaw 
cycle in liquid nitrogen and 37°C water bath, respectively. Intensive vortexing was applied 
in each cycle of freezing and thawing. The extracted proteins were collected in the 
supernatant by 10 min centrifugation at 14,000 rpm, 4°C. The total amount of protein was 




2.6. Working with HIT-T15 cells 
2.6.a. Transient transfection using DEAE-Dextran 
 The complex formation of DNA with DEAE-Dextran facilitates the endocytosis of 
DNA through cell membrane. This method was used for the analysis of reporter gene 
activity. TD-buffer was used for cell and DNA preparation. DEAE-Dextran was prepared at 
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the concentration of 60mg/ml in ddH2O, filtered by a 0.45 µm syringe filter and stored at 
4°C. 
TD-buffer  
Tris-HCl pH 7.4 25 mM 
NaCl 140 mM 
KCl 5 mM 
K2HPO4 0.7 mM 
The buffer was autoclaved for 20 min at 121°C and stored at room temperature. 
 
 One 15-cm-confluent dish of HIT-T15 cells was used to split to twelve 6-cm-
dishes. After detaching the cells from dish by trypsin/EDTA, the cells were collected in 7 
ml of pure RMPI medium and washed once with 10 ml of TD-buffer. The cells were re-
suspended in 1 ml/dish TD-buffer and supplemented with 5 µl DEAE-Dextran per dish. 2 
µg/dish of plasmid DNA was prepared in 2 ml of TD-buffer and added to the cells. In the 
case of cotransfection of plasmids the final amount of DNA was equilibrated by 
pBluescript vector. The cells' suspension was incubated at room temperature for 15 min. 
The cell were pelleted by centrifugation at 800 rpm for 2 min, washed with RPMI complete 
medium, and re-suspended in 5 ml/dish RMPI complete medium and seeded into 6-cm-
dishes. After 48 hrs incubation at 37°C, the cells were treated with additional agents and 
harvested for the measurement of reporter gene activity. 
 
2.6.b. Transient transfection by metafectene  
 This method was used for the analysis of overexpressed proteins in HIT-T15 cells. 
One 15-cm-dish was split to eight 6-cm-dishes. Transfection was performed according to 
the instruction of manufacturer. 2 µg DNA was added to 200 µl RPMI per dish. 4 µl 
Metafectene prepared in 200 µl RPMI per dish, keeping a 1 to 2 ratio between DNA and 
metafectene. The prepared solutions were mixed together and incubated at room 
temperature for 15 min. The mixture was added to the cells during the first hour of 
seeding. 48 hrs after incubation, the cells were used for the next experiment.  
  
2.6.c. Transient transfection by Oligofectamine 
 This method was used for the down-regulation of endogenous DLK by small 
interfering RNA (siRNA). 300.000 cells per well were seeded in 6-well plate and incubated 
for 24 hrs at 37°C. The next day, the cells were washed with pure RPMI to remove the 
sera which are included in complete medium, and supplemented with 800 µl OptiMEM® 
medium, a modified EMEM (Eagle's Minimum Essential Media) medium which is suitable 
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for lipid transfection. The cells were put back to the incubator. Oligofectamine and the 
siRNA were prepared according to the manufacturer's instruction. 
 
Per 2 wells Per 2 wells 
5 µl siRNA (50 pmol/well) 8 µl Oligofectamine 
ad 370 µl OptiMEM® 22 µl OptiMEM® 
 
The solutions were incubated at room temperature for 5 min and subsequently mixed 
together and incubated for another 15 min at room temperature. 200 µl of the mixture was 
added to each dish and incubated for 4 hrs at 37°C. 500 µl of 3x RPMI (3 times 
concentrated for FCS, HS, and pen/strep) were added to the wells and incubated for 24 
hrs.  
 
2.6.d. Cell harvesting for reporter gene assay 
The buffer used are listed below.  
Scraping buffer 1x 
Tris-HCl pH 7.5 40 mM 
EDTA 1 mM 
NaCl 150 mM 
 
KPi buffer pH 7.8  540 ml 
K2HPO4 100 mM 500 ml 
KH2PO4 100 mM ad 540 ml 
The pH of basic K2HPO4 was adjusted to 7.8 by acidic KH2PO4. The buffers were stored at 
room temperature. 
 The medium was removed and the cells were washed with PBS. The cells were 
mechanically detached from the dish using a cell scraper and collected in 1.5 ml scraping 
buffer. The cells were pelleted by 4 min centrifugation at 5000 rpm, at 4°C. The 
supernatant was discarded and the pellet was re-suspended in 150 µl of KPi buffer, 
freshly supplemented with 1 mM DTT. The samples underwent three freeze-thaw cycles 
in liquid nitrogen and 37°C water bath, respectively. Intensive vortexing was applied in 
each cycle. The samples were centrifuged at high speed for 10 min at 4°C using a table 
centrifuge. The supernatant was kept frozen at -80°C until measurement.   
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2.6.e. Immunocytochemistry 
 The subcellular localization of DLK wild-type and DLK PP mutant (mutation in 
leucine zipper) was analyzed by immunocytochemistry. 300.000 HIT-T15 cells were 
seeded on a coverslip in 6-well plate. The cells were transfected by the expression 
vectors for DLK wild-type and PP mutant by the Metafectene method. 48 hrs later the cells 
were treated with 10 ng/ml TNFα for 1 hr. Coverslips were transferred to new 6-well plate 
and washed 5 min with PBS agitating on a rocking platform at room temperature. The 
cells were fixed by 4ml methanol (-20°C) for 10 min and then washed 3 times with PBS for 
5 min each. To prevent nonspecific binding of antibodies the samples were blocked with 
blocking buffer for 45 min at room temperature and then washed once with PBS. The 
appropriate dilution of the primary anti-flag antibody was prepared and incubated with the 
samples overnight at 4°C. The next day, the samples were rinsed in PBS 3 times for 5 min 
each, and incubated with the secondary fluorescent labeled antibody for 30 min in a dark 
place. After rinsing 3 times in PBS for 5 min each, one droplet of Vectashield® mounting 
medium containing DAPI (4',6-diamino-2-phenylindole) was dropped on a glass slide and 
the coverslip lain down on it. The slides were left in a dark place for fixation. The imaging 
was performed using a Zeiss Axiovert 200M with Apo Tome Microscope and Axiovert 4.7 
software. 
The buffers were prepared in PBS as follows:    
             
Blocking buffer  
BSA 1% (w/v) 
Horse serum 10%(v/v) 
 
Antibody-dilution buffer  
BSA 1% (w/v) 
The buffers were prepared freshly before use. 
 
2.7. Luciferase assay 
The buffers and solutions used are listed below. 
Glycylglycine buffer  
Glycylglycine pH 7.8 25 mM 
MgSO4 15 mM 
EGTA 4 mM 
This buffer was stored at 4°C. 
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Luciferin stock  180 ml 
DTT 10 mM 275 mg 
Luciferin 1 mM 50 mg 
Glycylglycine buffer  178.5 ml 
The stock was stored as aliquots at -80°C. 
 Luciferase-assay mix  For 25 samples 
Glycylglycine buffer  7.5 ml 
KPi buffer 16.5 mM 1.5 ml 
ATP 2 mM 100 µl of 200 mM ATP 
DTT 1 mM 10 µl of 1 M DTT 
This buffer was prepared freshly before use. 
 
Luciferin solution  For 25 samples 
Glycylglycine buffer  5.6 ml 
DTT 10 mM 56 µl of 1 M DTT 
luciferin 250 µM 1.4 ml of Luciferin stock 
This solution was prepared freshly before use. 
 
 Luciferase refers to a class of oxidative enzymes participating in bioluminescence. 
Firefly luciferase from firefly photinus pyralis is a well-known member of this class of 
enzymes (Gould and Subramani 1988). The recombinant form of this enzyme is 
commercially available. Luciferin is the substrate of the enzyme. Luciferase catalyzes the 
reaction in two steps: 
1. Luciferin + ATP         Luciferyladenylate + PPi 
2. Luciferyladenylate + O2         Oxyluciferin + AMP + photon of light 
Oxyluciferin is electronically excited and emits a photon of light when turning back to its 
ground state. 
 50 μL of cell extract were mixed with 368 μL of luciferase-assay mix in a 
luminometer tube. Luciferase-assay mix was used as blank. 200 μL of the luciferin 
solution were injected automatically by the luminometer to the samples and the light 
emission was measured at 560 nm for 20 sec per sample.  
 
2.8. GFPtpz fluorescence  
The transfection efficiency values for luciferase reporter-gene assay was corrected to 
cotransfected pGFPtpz-CMV® vector. GFPtpz (GFP topz) contains 4 point mutations 
which shift emission spectrum from 504 nm to 527 nm (green to yellow) (Tsien 1998).  
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 50µl of cell extract from each sample were used to measure the GFP fluorescence 
in a 96-well microplate using a fluorometer (Fusion). Excitation wavelength was at 485 nm 
and the emission wavelength was measured at 530 nm. The data were analyzed by the 
software supplied with the device (Fusion InstrumentControl Application version 3.50, 
Canberra-Packard).   
 
2.9. Statistics 
The raw data were analyzed by one-way analysis of variance (ANOVA), Student’s t-test, 











3.1. Regulation of DLK 
3.1.a. Potential phosphorylation sites in DLK  
 According to a report (Leung and Lassam 2001) for MLK-3 (mixed Lineage 
Kinase-3), MLK family members have two putative autophosphorylation sites. The 
corresponding autophosphorylation sites for DLK are Serin-298 and Serin-302 residues. 
The mutant constructs of DLK coding sequence have been generated using a point 
mutation strategy for Serin-298 and Serin-302 residues (Fig. 3.1.A). 
 To investigate the expression level of the mutant constructs, HIT-T15 cells were 
transiently transfected with the constructs using Metafectene (chapter 2.6.b). The 
expression vector for DLKwt (wild-type) was used as positive control and the pBluescript 
vector was used as negative control.  
 48 hrs after transfection, the cells were harvested and the protein lysates were 
subjected to SDS-PAGE (sodium dodecyl sulfate - polyacrylamide gel electrophoresis) 
and immunoblotting. An antibody against the C-terminal of DLK protein was used to detect 
the expression of the protein (Fig. 3.1.B). An equally expression level of DLKwt and 
mutant proteins was observed, suggesting that the mutations had no effect on the 
expression of the proteins. 
 
DLK wt:               …TSKELSDKSTKMSFAGTVAWM… 
DLK S298A:        …TSKELSDKATKMSFAGTVAWM… 
DLK S302A:        …TSKELSDKSTKMAFAGTVAWM… 
DLK S298/302A: …TSKELSDKATKMAFAGTVAWM… 
 
                                       DLKwt   K185A   S298A    S302A       BS      S298/302A 
                                  
 
Figure 3. 1 Overexpression of DLK and its mutants in HIT-T15 cells. A. using the point 
mutation method, Serin-298 and Serin-302 residues of DLK were replaced by Alanine. B. HIT cells 
were transiently transfected with 2 µg of the expression vectors. DLK was detected using an anti-
DLK antibody which detects the C-terminus of DLK peptide (Holzman et al,. 1994). The blot 
presents an equally expression level for DLKwt and the mutants. The migration on the gel is slightly 
affected by the mutation in K185 and S302 residues. 
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3.1.b. DLK and the regulation of gene transcription 
3.1.b.I. DLK and CRE-directed gene transcription 
DLK inhibits CRE (cAMP response element) -directed gene transcription in HIT-T15 cells, 
whereas its kinase dead mutant (K185A) does not (Oetjen, Lechleiter et al. 2006). To 
investigate the effect of the mutation of DLK in Serin-298 and Serin-302 residues on CRE-
directed gene transcription, 0.6 µg of DLKwt and its mutant constructs were cotransfected 
with 2 µg of p4xSomCRELuc plasmid, using DEAE-Dextran method into HIT-T15 cells. 
The cells were treated with KCl (40 mmol/L) 6 hrs before harvesting. The cell lysates were 
extracted and the luciferase activity was measured (chapters 2.6.d and 2.7). DLKwt and 
DLK S298A mutant decreased CRE-dependent gene transcription stimulated by KCl. DLK 










Figure 3. 2 Regulation of CRE-directed gene transcription by DLK. A. Schematic figure of 
CRE-luciferase construct. B. The luciferase activity is relative to the stimulated control cells with no 
DLK transfection. Values are mean ± SEM of three independent experiments, each done in 
duplicate. p≤0.05 vs control.  
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3.1.b.II. DLK and CBP-dependent gene transcription 
DLK inhibits the membrane-depolarization induced transcriptional activity of the β-cell 
protective factor CREB (cAMP response element binding transcription factor) and its 
coactivator CBP (CREB binding protein) in HIT-T15 cells, whereas DLK kinase dead 
mutant does not (Oetjen, Lechleiter et al. 2006). To examine the role of phosphorylation 
sites of DLK in its inhibitory effect on CBP-dependent gene transcription in HIT-T15 cells, 
0.6 µg of DLK and its mutants were cotransfected along with 2 µg of 5xGal4E1BLuc 
plasmid, 2 µg of Gal4-CBP plasmid and 0.75 µg of GFPtpz as internal control for 
transfection efficiency using DEAE-Dextran. The cell lysates were extracted and the 
luciferase activity was measured (chapters 2.6.d and 2.7). DLKwt and DLK S298A mutant 
decreased CBP-dependent transcription, whereas DLK K185A, S302A, and S298/302A 







Figure 3. 3 Regulation of CBP-dependent gene transcription by DLK. A. Schematic figure of 
GAL4-CBP and 5xGal4E1BLuc constructs. B. Luciferase activity is corrected to GFP values in 
each experiment and is relative to control with no DLK transfection. Values are mean ± SEM of 
three independent experiments, each done in duplicate. p≤0.05 vs control.   
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3.1.c. Phosphorylation of JNK by DLK 
The stress activated protein kinase JNK is activated by different stress signals like pro-
inflammatory cytokine TNFα. Like other members of MLK family DLK phosphorylates and 
activates JNK (chapter 1.3). In this study the role of putative phosphorylation sites of DLK 
in the phosphorylation of JNK was investigated. HIT cells were transiently transfected with 
DLKwt and mutant vectors. The antibiotic Anisomycin was used as positive control which 
phosphorylates JNK. Forty eight hours after transfection the cell lysates were extracted 
and subjected to SDS-PAGE. The phosphorylation level of JNK was measured with an 
antibody against phosphorylated JNK. DLKwt increased the phosphorylation of JNK. 
Mutation in K185 and S302 residues diminished the phosphorylation of JNK by DLK. 
Mutation in S298 residue had no effect on the activation of JNK by DLK. 
  
 
Figure 3. 4 Phosphorylation of JNK by DLK. A. A typical immunoblot picture detected by an 
antibody against phosphorylated JNK. HIT cells were transiently transfected with DLKwt and 
mutant vectors. The cells were harvested 48 hrs after transfection and the proteins were subjected 
to SDS_PAGE. BS: pBluescript, Aniso: Anisomycin. B. The optical density of p-JNK is corrected to 
the optical density of GAPDH for each experiment and is relative to DLKwt. Anisomycin as a 
potential activator of JNK caused high level of JNK phosphorylation. Values are mean ± SEM of 
three independent experiments, each done in duplicate. *p≤0.05, one way ANOVA. 
A 
B 
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3.1.d. Phosphorylation specific anti-DLK antibody  
 A phosphorylation specific antibody was produced which detects the 
phosphorylation of DLK at Serin-302 residue. HIT-cells were transiently transfected with 
expression vectors (chapter. 2.6.b). Forty eight hours after transfection the cell lysates 
were extracted and subjected to SDS-PAGE. The phosphorylation of DLK at Serin-302 
residue was detected by the phosphorylation specific antibody. DLK K185A is unable to 
bind to ATP. This expression vector was used as a negative control for 
autophosphorylation of DLK. The expression vectors carrying the K185A and S302A 
mutations showed no phosphorylation. 
 
 
                                    DLKwt           K185A       S302A         S298A       S298/302A 
                                  
Figure 3. 5 Phosphorylation of DLK at Serin-302 residue. The cells were transfected with each 
expression vectors. 48 hrs after transfection the cell lysates were subjected to SDS-PAGE. The 
phosphorylation of DLK was detected using the antibody which recognizes the phosphorylated 
Serin-302 residue specifically. The phosphorylation was detected for DLKwt and the S298A 
mutant.  
 
3.1.e. Regulation of DLK by proinflammatory cytokines 
A variety of cytokines is involved in the pathogenesis of type 2 diabetes. TNFα and IL-1β 
play a role in inducing β-cell apoptosis in type 2 diabetes (Maedler, Fontana et al. 2002; 
Donath, Storling et al. 2003). To examine the role of proinflammatory cytokines TNFα and 
IL-1β in phosphorylation and subsequently activation of DLK, HIT-T15 cells were treated 
with TNFα (30 ng/ml) and IL-1β (10 ng/ml) for 60 min. The effect of forskolin (10µM, 30 
min before harvesting), as an activator of adenylate cyclase, on the phosphorylation of 
DLK was also tested. The immunosuppressive drug cyclosporine A (5µM, 30 min before 
harvesting) was used as a positive control for DLK phosphorylation (Oetjen, Lechleiter et 
al. 2006; Plaumann, Blume et al. 2008). After harvesting, the total protein amount was 
measured by Bradford assay and 150 µg proteins were subjected to SDS-PAGE and 
immunoblotting. The expression level and the phosphorylation of DLK were detected with 
antibody against DLK and phospho-DLK, respectively. The optical density of the 
corresponding bands was measured and used for statistical analysis. No differences were 
observed in protein level of DLK in any experiments (Fig. 3.6). The amount of 
phosphorylated DLK at Serin-302 was increased by CsA, TNFα, and forskolin (Fig. 3.7). 
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Figure 3. 6 Proinflammatory cytokines and the expression of DLK. A. A typical immunoblot 
picture detected by an anti-DLK C-terminus antibody. The arrow shows the corresponding band for 
DLK. B. The optical density of DLK is corrected to the optical density of GAPDH for each 
experiment and is relative to control. Values are mean ± SEM of three independent experiments, 













































































Figure 3. 7 Phosphorylation of DLK. A. A typical immunoblot picture detected by an antibody 
against phosphorylated DLK at Serin-302 residue. The arrow shows the corresponding bands for 
phosphorylated DLK. B. The optical density of phosphorylated DLK is corrected to the optical 
density of GAPDH for each experiment and is relative to control. Values are mean ± SEM of three 
independent experiments, each done in duplicate. p≤0.05, One-way ANOVA.  
 
 
3.1.f. Interaction of DLK with importins 
 Karyopherins are responsible for transportation of protein molecules between 
cytoplasm and nucleoplasm as import and export which occurs through nuclear pore. 
Importin is a member of karyopherins which transport protein molecule from cytoplasm 
into the nucleus by binding to a specific recognition sequence in the protein molecules, 
called nuclear localization signal (NLS). Previous work of our group introduced two 
putative NLS in DLK whose mutation prevents DLK nuclear localization driven by pro-
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To investigate whether DLK interacts with karyopherins, required for nuclear 
translocation, a protein-protein interaction assay was performed. The putative interaction 
between DLK-NLS and three different members of importin (importin α, importin β, and 
transportin) was examined. DLK protein was purified and immobilized on amylose resin 
(chapter 2.5.e.III). The interaction was performed with purified importins (chapter 2.5.f), 
and the resin carrying DLK interacted with importin was subjected to SDS-PAGE and 
immunoblotting. Since the importins were His-tagged purified proteins, the interaction 
efficiency was detected using an anti-His antibody. Ponceau staining was used to detect 
the equal amount of immobilized DLK proteins. DLKwt interacts with importin α, but 
neither with importin β nor with transportin. DLK NLS1 mutant showed a faint interaction 
with importin α. No interaction is observed between DLK-NLS2 and none of the importins 
(Fig. 3.8 C). DLK-PP interacts with importin α (Fig. 3.8 D). 
 
                                    DLK NLSwt :      KKVRDLKETDIKHLRKLKH 
DLK NLS1  :      KAVADLKETDIKHLRKLKH 















Figure 3. 8 Interaction of DLK with three members of importins. A. The amino acid sequence 
of DLK NLS. The key residues constructing the bipartite NLS, and the relative mutations are shown 
in red. B. Equal amount of immobilized proteins was detected by ponceau staining. The band 
corresponded to MBP was detected at 50 kDa and the bands of MBP-fused DLK proteins are at 92 
kDa. The M letter labels the molecular weight ruler. C. The interaction between MBP-fused DLK 
proteins and three different importins was detected using an anti-His antibody. MBP was used as 
negative control. D. The interaction between MBP-fused DLK proteins and importin α was detected 
by anti-His antibody. 5% of total amount of importin α used for interaction (0.1 µg), was loaded as 
input. PP refers to DLK-PP mutant which has two point mutations in leucine zipper sequence. WT: 
DLKwt, NLS1: DLK NLS1, NLS2: DLK NLS2, MBP: maltose binding protein, α: importin α, β: 
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3.1.g. Nuclear localization of DLK wild-type and DLK-PP mutant 
 Two point mutations in leucine zipper part of DLK-PP (leucine-437 and leucine-463 
were replaced by proline) make it unable to homodimerize. The aim of this experiment 
was to investigate the effect of homodimerization of DLK on its nuclear localization. HIT 
cells were transiently transfected with DLKwt or DLK-PP mutant, which contain a FLAG-
epitope, using metafectene method (chapter 2.6.b). The cells were treated with TNFα (10 
ng/ml) for 60 min. The cells were prepared for immunostaining and stained with DAPI and 
anti-flag antibody (chapter 2.6.e). Microscopy was performed by Zeiss Axiovert Apo Tome 
microscope (Fig. 3.9). TNFα treatment led to increase in nuclear localization of DLKwt. 
Nuclear localization of DLK-PP was increased by TNFα compared to control, but was 





   
   
 
   
   















Figure 3. 9 Subcellular localization of DLKwt and DLK-PP mutant. A. Typical pictures of 
subcellular DLK. The blue color represents the nucleus stained by DAPI and the green color 
depicts DLK recognized by anti-flag antibody. The scale bar represents 1µm. B. HIT-cells were 
transfected with expression vectors and incubated for 47 hrs. The cells were treated with TNFα (10 
ng/ml) for one hour. The control was kept nontreated. The values show the percentage of nuclear 
localized DLK divided to total transfected cells from three independent experiments. p≤0.05, 
Pearson χ
2
 test.  
 
 
3.2 Effects of DLK on cell apoptosis 
3.2.a. Activation of caspase-3 by proinflammatory cytokines in HIT cells 
 It has been reported before that TNFα, alone or in combination with IL-1β and 
IFNγ , induces β-cell apoptosis (Ishizuka, Yagui et al. 1999; Bonny, Oberson et al. 2000; 
Haefliger, Tawadros et al. 2003; Jambal, Masterson et al. 2003). Overexpression of DLK 
results in cell apoptosis (Plaumann, Blume et al. 2008). To investigate whether DLK 
mediates the apoptosis induced by proinflammatory cytokines in β-cells the cleavage of 
caspase-3 was studied by immunoblot analysis. 24 hrs after seeding the cells were 
treated with TNFα (1000U/ml), IL-1β (10U/ml), IFNγ (100U/ml), the combination of IL-1β 
and IFNγ, and the combination of TNFα and IFNγ, for the next 24 hrs. The cells were 
harvested and the total amount of protein was determined by Bradford assay. 100 µg of 
protein was subjected to SDS-PAGE and immunoblotting. The cleavage of caspase-3 was 
detected using an antibody against caspase-3 which detects the large fragment (17/19 
kDa) of activated caspase-3 resulting from cleavage adjacent to Asp175. Treatment with 























































Figure 3. 10 The activation of caspase-3 by proinflammatory cytokines. A. A typical 
immunoblot picture detected by an antibody against activated caspase-3 which has been cleaved 
adjacent to Asp 175 residue. B. The optical density is corrected to GAPDH for each experiment 
and is relative to control. Values are mean ± SEM of three independent experiments, each done in 
duplicate. p≤0.05, One-way ANOVA.  
3.2.b. Intermediary role of DLK in the activation of capase 3 by proinflammatory 
cytokines  
 To study whether DLK is involved in β-cell apoptosis induced by proinflammatory 
cytokines, endogenous DLK was downregulated by small interfering RNA (chapter 2.6.c). 
24hrs later, the cells were treated with TNFα (1000 U/ml) and TNFα in combination with 
IFNγ (100 U/ml), for the next 24 hrs. The cells were harvested and the total amount of 
protein was measured by Bradford assay. 80 µg of protein was subjected to SDS-PAGE 
and immunoblotting. No efficient down regulation of DLK is observed in HIT cells by DLK-
specific siRNA (Fig. 3.11 B). TNFα increased the amount of cleaved caspase 3 in both 
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Figure 3. 11 Role of DLK in β-cell apoptosis induced by proinflammatory cytokines. A. 
Typical immunoblot membrane detected by anti-DLK C-terminus, anti-cleaved caspase-3, and anti-
tubulin antibodies. B. Downregulation of DLK by anti-DLK siRNA. Values are mean ± SEM of four 
independent experiments, each done in duplicate. C. Cleavage of caspase 3. The optical density 
is corrected to α-tubulin for each experiment and is relative to control. Values are mean ± SEM of 
four independent experiments, each done in duplicate. p≤0.05, One-way ANOVA. 
3.3 Animal experimentation; role of DLK in diet-induced diabetes 
The role of DLK in diet-induced diabetes was investigated in C57BL/6J DLK-heterozygote 
mice and their wild-type littermates. The mice were divided into 3 groups of feeding, 
normal diet (ND), carbohydrate rich diet (CRD), and high fat diet (HFD). HFD contains 
30% fat. The feeding was started at the age of 8 weeks and continued for 16 weeks. The 
mice were weighted at the beginning of experiment and also every other week until the 
end of the experiments. The blood glucose was measured at the beginning of the 
experiment (day 0) and every four weeks until the end of experiments. The plasma level of 
glycated hemoglobin (HbA1c) was measured at the end of experiment. No significant 
increase was observed in the body weight of different genotype and different diet (Fig. 
3.12 A). No significant increase in blood glucose was observed in different genotypes and 
different diet (Fig. 3.12 B). Plasma level of HbA1c was increased in heterozygote mice 
under HFD compared to ND at the end of experiment (Fig. 3.12 D). No difference was 
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Figure 3. 12 Role of DLK in diet-induced diabetes. A. wild-type (+/+) and heterozygote (-/+) 
mice (10 per each group) were fed with different diets for 16 weeks. Values represent the increase 
of weight after 16 weeks of diet and are relative to the weight of each mouse at the beginning of 
diet. p≤0.05, student t-test. B. The values are mean ± SEM of blood glucose at week 16 relative to 
blood glucose of each mouse at the beginning of the experiment. p≤0.05, student t-test. C. The 
plasma level of HbA1c (glycated hemoglobin) was measured at the end of experiment. No 
significant difference in plasma level of HbA1c was detected in wild-type mice with different diet at 
the end of experiment. p≤0.05, student t-test. D. Plasma level of HbA1c was increased in 
heterozygote mice under HFD compared to ND at the end of experiment. p≤0.05, student t-test. E. 
No difference was observed in HbA1c between wild-type and heterozygote mice under HFD. 
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3.4 Generation of a targeting knock-out vector for DLK 
3.4.a. Sequencing of genomic DLK in 129Sv mouse strain 
129Sv-derived embryonic stem (ES) cell lines are considered to be more reliable in 
colonizing than ES cells derived from other strains. 32 pairs of PCR primers were 
designed to amplify the full length sequence of DLK from a genomic DNA extracted from 
129Sv strain. The primers were designed in a way that each amplified fragment overlaps 
at least 50 bp of the downstream fragment. The sequencing was performed according to 
chain-termination method (chapter 2.4.j). The resulted sequence was compared to the 
sequence of C57BL/6J strain which is available electronically in Ensembl Genome 
Browser. No mismatches were observed in DLK sequences between C57BL/6J and 
129Sv strains.   
 
 
Figure 3. 13 A typical picture of DLK sequence, comparing between 129Sv and C57BL/6J 
strains. The upper sequence labeled DLK.txt is referring to DLK in C57BL/6J strain. 21f_F01 is a 
part of the sequence of the fragment 21, and 22r_H01 is a part of the sequence of fragment 22 
amplified from 129Sv strain. The overlapping nucleotides between two fragments guarantied the 
continues sequencing of all amplified fragments.  
     
3.4.b. Digestion pattern of bMQ317c09 
 Bacterial artificial chromosome (BAC) is widely used for sequencing the genome in 
genome projects, as well as generating the genetically modified animal models. The 
benefits of these plasmids are that they are able to carry an insert of 150-350 kb 
nucleotide, and to distribute evenly after bacterial cell division. The BAC plasmid 
bMQ317c09 containing the genomic sequence of DLK from 129Sv mouse strain was used 
to generate the targeting knock-out vector for DLK. Before retrieving the DNA from BAC 
plasmid into the targeting vector the BAC DNA was digested with NotI restriction enzyme 
and the digestion pattern was compared to the prepared map. Three different fragments 
are expected from digestion after running the agarose gel using a pulsed-field system 
Results  
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(80.2 kb, 71.77 kb, and 8.73 kb) (Fig. 3.14 A and B). The expected fragments after 
digestion are shown by the arrows (Fig. 3.14 B). 
                             
 
 
Figure 3. 14 Digestion pattern and map of bMQ317c09 plasmid. A. The map of bMQ317c09 
and the restriction digestion sites of NotI and the corresponding fragments’ size. B. Typical picture 
of a TBE gel used to run the digested DNA on a pulsed-field system. The arrows on the right show 
the expected fragments after digestion. The mid-range and low-range pulsed-field gel (PFG) 




3.4.c. Generation of homology arms and the retrieval plasmid 
 To retrieve the sequence of interest from BAC plasmid into the targeting vector two 
homology arms was generated up- and downstream of the sequence of interest, by PCR 
amplification using two pairs of primers. The first homology arm is located in the 
sequences between 63627130-63627580bp and the second one is between 63616689-
63617174bp on chromosome 15 of C57BL/6J mouse strain. The homology arms were 
amplified by PCR reaction, digested with restriction enzymes (NotI, HindIII, and SpeI), 
purified and inserted into the PL253 plasmid which had been linearized by NotI and SpeI. 
























           
         
      
Figure 3. 15 Retrieval plasmid contains homology arms. A. The map of retrieval plasmid with 
the homology arms inserted. B. Digestion pattern of the retrieval plasmid after digestion with NotI 
and SpeI restriction enzymes. 10 positive colonies were picked and the DNA was extracted. The 
colonies carrying the retrieval plasmid were defined by digestion with NotI and SpeI.  
 
 
3.4.d. Retrieval of DNA from BAC  
 SW102 cells were transformed with the BAC DNA. The positive colonies 
containing a chloramphenicol resistance made by BAC plasmid were selected on a 
chloramphenicol agar plate. DNA was extracted and digested with NotI restriction enzyme 
to prove the accuracy of the plasmid. The digestion pattern was compared to the pattern 
described in section 3.4.a.  
 The positive bacteria were induced for Red recombination function (chapter 
2.4.k.II.2). The retrieval plasmid from the previous step was linearized with HindIII and gel 
purified. The induced bacteria were transformed with linearized plasmid and the positive 
recombinant cells were selected on an Amp+ agar plate. The DNA was extracted and 
digested with EcoRI and compared to the prepared map. One colony showed successful 















                                       
  
                                                   
Figure 3. 16 Retrieving of DNA from BAC plasmid. A. The map of targeting vector after DNA 
retrieved from BAC plasmid. The restriction digestion sites for EcoRI and the resulted fragments 
are depicted. B. The DNA extracted from SW102 transformed with BAC plasmid was digested with 
NotI and run on a TBE gel using a pulsed-field system. The pattern is the same as the digestion 
pattern of the BAC plasmid before transformation. C. The DNA extracted after homologous 
recombination retrieval of DNA from BAC plasmid into targeting vector was restriction digested with 
EcoRI and the positive recombinant colony was selected according to the map.  
 
 
3.4.e. Generation of mini-targeting vectors 
 To introduce the loxP sites in the targeting vector two pairs of PCR primers were 
designed to amplify two homology arms up- and downstream to the point of loxP 
insertion point. The homology arms were amplified using a PCR reaction and the 
bMQ317c09 DNA as template. The homology arms CD and EF are located on 
chromosome 15 of C57BL/6J mouse strain between 63622426-63622204bp and 
63622632-63622427bp, respectively. The homology arms GH and IJ are located on 
chromosome 15 of C57BL/6J mouse strain between 63620524-63620317bp and 
63620718-63620525bp, respectively. To generate the first mini-targeting vector the neo 
cassette flanked by loxP was cut out of the PL452 plasmid and ligated along with the 
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arms GH and IJ were ligated along with the neo cassette plus loxP flanked by FRT, 
which had been cut out of the PL451 plasmid, into pBluescript plasmid (Fig. 3.17 B). 
Four out of five colonies were positive with generated mini-targeting vector. The 
successful ligated fragments were cut out of the plasmid and purified for the 
homologous recombination insertion of loxP site into the targeting vector. (Fig. 3.17 C). 
                                            
                               
                                          
Figure 3. 17 Generation of mini-targeting vector. A. The map of the first mini-targeting vector 
which was used to insert the loxP site upstream to the exon 3 of DLK in targeting vector. B. The 
map of the second mini-targeting vector which was used to insert the second loxP site downstream 
to the exon 6 of DLK in targeting vector. C. Four out of five colonies were positive with generated 
mini-targeting vector. The homology arms (HR) and the neo cassette flanked by loxP sites were cut 
out together from the mini-targeting vector by NotI and SalI restriction digestion, and purified from 
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3.4.f. Introduction of the first loxP site 
 To introduce the first loxP site into the targeting vector (3.4.c) SW102 cells 
carrying the targeting vector were induced for Red recombination function as 
described before. The induced cells were transformed with the loxP containing 
fragment (Fig. 3.17.A, C). The successfully recombinant cells were selected on a 
kanamycin agar plate, since the recombinant vector contains the neo cassette. 
The recombinant DNA was extracted and subjected to a restriction digest with 
EcoRI. The digestion pattern was compared to the prepared map and the 
positive colonies were selected for the next step. The digestion pattern defines the 
successful recombination, thereby the integration of the flanked neo cassette by loxP 








Figure 3. 18 Introduction of the first loxP site into the targeting vector. A. The map of the 
targeting vector with the neo cassette flanked by loxP sites inserted upstream to the exon 3 of DLK. 
B. The extracted vector was digested with EcoRI and the three expected fragments was compared 
to the map.  
 
3.4.g. Excision of the neo cassette 
Before introducing the second loxP sites, which will be selected also by kanamycin 
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recombination activity of Cre-recombinase which recognizes the loxP sites and cuts out 
one of the loxP sites and the sequences flanked between the two loxPs. SW106 
bacteria in which Cre-recombinase is already induced (chapter 2.4.k.II.5) were 
transformed with the targeting vector containing neo cassette flnaked by two loxP sites. 
The successful Cre-recombinase activity resulted in neo cassette excision, which can be 
selected on ampicillin agar plates and negative selection on kanamycin agar plates. The 
DNA was extracted from the cells and digested with SpeI. The digestion pattern was 
compared to the map, showing the successful remove of neo cassette from the targeting 
vector (Fig. 3.19).  
    
                         
 
 
                                   
 
Figure 3. 19 Excision of the neo cassette. A. The map of the targeting vector after excision of 
the neo cassette. Cre-recombinase cut one loxP site and the neo cassette. B. The extracted DNA 
from ampicillin resistant colonies was digested with SpeI.  
 
 
3.4.h. Introduction of the second loxP site 
SW102 bacteria were transformed with targeting vector which contains one loxP site and 
induced for Red recombination function as described before. The induced cells were 
transformed with the purified fragment from second mini-targeting vector (Fig. 3.17. B and 
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extracted and digested with EcoRI and the digestion pattern was compared to the map. 
Both selected colonies which are kanamycin resistant, carrying the neo cassette flanked 
by loxP and FRT sites (Fig. 3.20). 
 
 





Figure 3. 20 Introduction of the second 
loxP. A. The map of the targeting vector with 
the second loxP site inserted. The neo 
cassette is flanked by two FRT sites which 
can be removed by flippase (flpe). B. DNA 
was digested with EcoRI and the digestion 
pattern was compared to the map.  
  
 
                          
 
 
Figure 3. 21 Schematic figure of the generated targeting knock-out vector for DLK. Exons 3, 
4, 5, and 6 are flanked by two loxP sites. The Cre-recombinase cut the flanked exons out by 
recognizing the loxP sites. This vector can be used to generate a conditional knock-out mice model 


























4.1 Regulation of DLK by prediabetic signals 
4.1.a. Enhancement of kinase activity of DLK 
 DLK was identified as a member of MLK family and known as a MAPKKK, 
expressed in the brain and peripheral nervous system as well as primary murine islets and 
the β-cell line HIT. Its activity resulted in the activation of downstream MAPKKs and 
consequently the activation of specific MAPKs (Holzman, Merritt et al. 1994; Oetjen, 
Grapentin et al. 2003; Hirai, Kawaguchi et al. 2005). Later on, an ATP-binding site was 
identified in DLK protein whose mutation led to catalytic disability of the kinase (Mata, 
Merritt et al. 1996). The putative autophosphorylation sites in MLK family members have 
been identified (Fig. 1.6) (Leung and Lassam 2001). The potential autophosphorylation 
sites, Serin-298 and Serin-302, in DLK were studied by generation of point mutations in 
these residues, in our research group (Fig. 3.1A). In this study the expression of DLKwt 
and the mutants were examined in HIT cells (Fig. 3.1B). Using an anti-DLK antibody it 
was identified that the mutations in autophosphorylation sites and the ATP-binding site do 
not affect the expression of the DLK protein in HIT cells. In addition a slightly faster 
migration was observed for the kinase dead mutant (K185A) and the Serin-302 (S302A) 
mutant on the immunoblott membrane, which might be because of the disability of these 
mutants to autophosphorylate (Fig. 3.1).  
   The glucose oxidation in pancreatic β-cells induces the membrane depolarization 
via closure of KATP channels, leading to calcium entry through voltage-sensitive L-type 
calcium channels, and consequently the phosphorylation and activation of the 
transcription factor CREB (Docherty and Clark 1994; Schwaninger, Blume et al. 1995; 
Jhala, Canettieri et al. 2003), an essential factor for β-cell function and survival (Eggers, 
Siemann et al. 1998; Jambal, Masterson et al. 2003; Jhala, Canettieri et al. 2003; Eliseev, 
Vanwinkle et al. 2004; Hsieh, Chen et al. 2005). CREB is a transcription factor which 
binds to and mediates the membrane depolarization responsiveness of the CRE in the 
regulation of insulin gene transcription (Oetjen, Diedrich et al. 1994; Eggers, Siemann et 
al. 1998; Oetjen, Grapentin et al. 2003). The overexpression of CREB in MIN6 β-cells 
prevented the cytokines-induced apoptosis (Jambal, Masterson et al. 2003) while the β-
cell specific overexpression of a dominant-negative CREB mutant in mice caused β-cell 
apoptosis and diabetes (Jhala, Canettieri et al. 2003). In addition the disruption of the 
CRE-mediated transcription by overexpression of inducible cAMP early repressor (ICER) 
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in mice led to reduced expression of the insulin and the cyclin A genes, β-cell decline and 
severe diabetes (Inada, Hamamoto et al. 2004). 
 In the physiological state in β-cells, ATP produced from glucose metabolism 
induces the closure of the ATP-sensitive potassium (KATP) channels. The L-type voltage-
dependent calcium channels (VDCCL) sense the membrane depolarization followed by the 
closure of KATP channels and open (Drews, Krippeit-Drews et al. 2010). The increased 
Ca2+ influx triggers the downstream Ca2+-dependent cascades like CamK which activates 
CREB (Ban, Yamada et al. 2000). The signals which induce protein kinase C (PKC) has 
also been shown to activate CREB (Brindle and Montminy 1992; Mayr, Canettieri et al. 
2001). DLK was shown to inhibit the membrane depolarization-induced transcriptional 
activity of CREB in a β-cell line (Oetjen, Lechleiter et al. 2006). The activation of DLK by 
immunosuppressive drug cyclosporin A leads to β-cell apoptosis and β-cell mass decline 
(Plaumann, Blume et al. 2008). Cyclosporin A has been reported also to inhibit glucose-
induced insulin gene transcription and CREB transcriptional activity through inhibition of 
calcineurin, which might participate in post-transplant diabetes under immunosuppressive 
drug therapy (Oetjen, Grapentin et al. 2003). CRTC (CREB regulating transcriptional 
coactivator) is a coactivator of CREB which interacts with CREB and participates in 
CREB-dependent gene transcription (Screaton, Conkright et al. 2004). The phosphatase 
calcineurin which is activated by elevated intracellular calcium, dephosphorylates CRTC 
thereby leading to its nuclear translocation, where CRTC interacts with CREB (Jansson, 
Ng et al. 2008).It has been reported that DLK inhibits CRTC function by phosphorylation 
on its inhibitory sites (Phu do, Wallbach et al. 2011). Then it could be proposed that 
glucose-induced membrane depolarization in one hand triggers the CRE-directed gene 
transcription, and in the other hand induces the Ca2+-dependent phosphatase calcineurin 
which might dephosphorylate and deactivate DLK and dephosphorylate and activate 




















Figure 4. 1 CRE-directed gene transcription in β-cells. ATP produced from the oxidation of 
glucose blocks the ATP-sensitive potassium channels (KATP) leading to membrane depolarization 





 activates the Ca
2+
-dependent protein kinase (PKC), and the Ca
2+
-modulated 
protein calmodulin (CaM). PKC triggers downstream cascade which finally leads to the activation of 
extracellular signal-regulated kinase (ERK) 1/2 and consequently the activation of CREB/CRE-
dependent gene transcription. Ca
2+
/CaM activates the Ca
2+
/CaM-dependent phosphatase 
calcineurin (CN) which might dephosphorylate and deactivate DLK. When CN is inhibited DLK 
phosphorylates and activates JNK which does in return release DLK from JIP (JNK interacting 
protein). The released homodimerized DLK might translocate into the nucleus and inhibits the 
CREB/CRE-dependent gene transcription. Glut; glucose transporter, CBP; CREB binding protein. 
  
 
 In this study the role of the putative phosphorylation sites of DLK in the regulation 
of CRE-directed gene transcription was investigated (Fig. 3.2). DLKwt inhibited the CRE-
directed gene transcription, while the kinase dead mutant DLK K185A showed no 
inhibitory effect which is in accordance to the previous report (Oetjen, Lechleiter et al. 
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transcription, while the DLK S302A mutant and the DLK S302/298A double mutant were 
unable in such an inhibitory effect. These data clarify that the Serin-302 is an important 
residue for the phosphorylation and activation of DLK. 
 As previously reported DLK inhibits the transcriptional activity of the CREB 
coactivator CBP triggered by membrane depolarization, while the DLK K185A mutant 
does not (Oetjen, Lechleiter et al. 2006). DLK might directly phosphorylate CBP on the 
inhibitory sites which disrupts its interaction to the CREB (Xu, Maroney et al. 2001). In this 
study the role of the putative phosphorylation sites in the regulation of CBP-dependent 
gene transcription was investigated (Fig. 3.3). DLKwt inhibited the CBP-dependent gene 
transcription, whereas the DLK K185A mutant did not. This result proves the previous 
report for the inhibitory effect of DLK on CBP-dependent gene transcription (Oetjen, 
Lechleiter et al. 2006). While DLK S298A mutant also inhibited the CBP-dependent gene 
transcription DLKS302A and DLK S302/298A mutants showed no inhibitory effect.  
JNK is a member of the MAPK family that is activated by different stimuli, including 
cytokines, reactive oxygen species (ROS), and MAPKKKs. MAPKKKs activate JNK 
through MKK4 and MKK7 by phosphorylation of JNK at threonine (Thr) and tyrosine (Tyr) 
residues in its activation loop (Kallunki, Deng et al. 1996). MKK7 mediates the cytokine-
induced JNK activation by phosphorylation of the Thr residue (Haeusgen, Herdegen et al. 
2011). The initial activation of JNK by TNFα is transient and leads to cell proliferation 
through AP-1 (activator protein-1), but sustained activation of JNK leads to cell apoptosis 
(Karin and Lin 2002; Micheau and Tschopp 2003; Ventura, Cogswell et al. 2004; Wagner 
and Nebreda 2009). DLK has been also reported to activate JNK (chapter 1.3). In this 
study the role of the putative phosphorylation sites of DLK on the activation of JNK was 
investigated (Fig. 3.4). Mutation in the ATP-binding site of DLK (K185A) which prevents 
DLK autophosphorylation, diminished the phosphorylation of JNK by DLK. Mutation at 
Serin-302 residue of DLK decreased the phosphorylation of JNK by DLK, where mutation 
at Serin-298 residue had no effect. Taken together these data suggest that DLK needs to 
be phosphorylated at Serin-302 residue to be catalytically active. 
 Knowing the importance of Serin-302 residue in the phosphorylation and activation 
of DLK necessitated establishing a reliable detection method to detect this 
phosphorylation site. A phospho-Serin-302 specific antibody was produced which detects 
the phosphorylated Serin-302 residue in DLK protein. Using this antibody the 
phosphorylated overexpressed DLKwt and DLK S298A mutant were detected in an 
immunoblot analysis. DLK S302A and DLK S302/298A mutants were not detectable. Due 
to a mutation in ATP-binding site DLK K185A mutant was remained unphosphorylated, 
too (Fig. 3.5). These data show that the generated antibody specifically recognizes the 
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phosphorylation on Serin-302 residue of DLK and provides a tool for determining DLK 
activity.  
 The involvement of a variety of cytokines in the pathogenesis of both T1DM and 
T2DM has been widely reported (chapter 1.2). As discussed in section 4.1.b., when 
activated, DLK inhibits the transcriptional activity of the β-cell protective factor CREB. In 
this study the regulation of DLK by two major pro-inflammatory cytokines, TNFα and IL-
1β, involved in DM pathogenesis was investigated. The expression level of the 
endogenous DLK was unaffected by the cytokines (Fig. 3.6). CsA which activates DLK 
(Plaumann, Blume et al. 2008) and inhibits the CREB/CRE-directed gene transcription 
(Schwaninger, Blume et al. 1993; Kruger, Schwaninger et al. 1997)caused no increase in 
DLK protein expression. Forskolin, a diterpene natural product, which activates adenylyl 
cyclase had no significant effect on DLK protein expression. The cAMP signaling pathway 
plays an outstanding role in function and proliferation of pancreatic β-cells. The insulin 
secretagogue hormone glucagon-like peptide-1 (GLP-1) activates the adenylyl cyclase 
enzyme for cAMP production (Drucker 1998; Holst 1999; Kieffer and Habener 1999; Holz 
and Chepurny 2003). cAMP activates the cAMP-dependent protein kinase A (PKA) which 
directly induces the CREB/CRE-directed gene transcription (Montminy 1997; Daniel, 
Walker et al. 1998).  
 The phosphorylation of DLK was also investigated (Fig. 3.7). CsA significantly 
increased the phosphorylation of DLK. Where IL-1β caused no significant increase in DLK 
phosphorylation, TNFα phosphorylated the endogenous DLK in HIT cells. The activated 
DLK phosphorylates and activates the downstream kinase JNK, which is well known to be 
involved in apoptosis (Gallo and Johnson 2002). The activated JNK triggers the 
dissociation of DLK from JIP scaffold protein (Nihalani, Meyer et al. 2001; Nihalani, Wong 
et al. 2003), which might lead to DLK activation and the inhibition of CREB/CRE-directed 
gene transcription by DLK. Thus, the phosphorylation of DLK by TNFα might mediate the 
deleterious effects of TNFα in pancreatic β-cells. Forskolin also caused a significant 
increase in DLK phosphorylation. Beside PKA, EPAC (exchange protein activated by 
cAMP, also known as cAMPGEF: cAMP-regulated guanine nucleutide exchange factor) 
has been also identified to mediate the cAMP signaling (de Rooij, Zwartkruis et al. 1998; 
Kawasaki, Springett et al. 1998). Both PKA and EPAC induce calcium-induced calcium 
release from endoplasmic reticulum via ryanodin receptor, and consequently ATP 
production in mitochondria. They might also activate some other kinases such as CaMK, 
PI-3K, PKB (Akt), ERK1/2, and atypical PKC-ξ (Holz 2004).The mechanism/s by which 
cAMP might increase DLK phosphorylation needs further investigation, but what can be 
mentioned here is that glucose-induced membrane depolarization in one hand triggers the 
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CREB/CRE-directed gene transcription, on the other hand might inhibit DLK activity 
through induction of calcineurin. In contrast, cAMP signaling might show a dual activity, 
triggering the CREB/CRE-dependent gene transcription mediated by PKA and the 
activation of DLK by some other kinase which have been induced by PKA and/or EPAC, 
and consequently inhibition of CREB transcriptional activity. A witness to this idea could 
be the report in which DLKwt inhibited the CRE-directed gene transcription induced by 
membrane depolarization as well as cAMP induced gene transcription, while the DLK 
K185A mutant did not inhibit the membrane depolarization-induced gene transcription but 
inhibited the cAMP-induced transcription (Oetjen, Lechleiter et al. 2006), proposing a 
probable participation of cAMP-signaling pathway in the phosphorylation of DLK which is 
independent of the ATP-binding site.  
 
4.1.b. Nuclear localization of DLK 
 A well know characteristic of the eukaryotic cells is the separation of the genetic 
materials and the transcriptional machinery of the nucleus from the translational 
machinery and metabolic system of the cytoplasm by the nuclear envelope. This 
segregation simplifies the regulation of cellular processes such as signal transduction, 
gene expression and cell cycle control and progress. The precise regulation of these 
phenomena is dependent on a bidirectional transport between the cytoplasm and the 
nucleus. Such a crucial process needs molecular machinery which recognizes the cargo 
in one compartment, translocates it through the nuclear envelope, and releases it in the 
other compartment. This kind of nuclear transport system was first identified around 30 
years ago by characterizing a nuclear targeting signal in the simian virus 40 (SV40) large 
T-antigen (Kalderon, Richardson et al. 1984; Kalderon, Roberts et al. 1984). Since then, 
several nucleocytoplasmic transport pathways have been proposed, of which the classical 
nuclear import pathway is the best globally accepted. The transportation of the 
macromolecules into and out of the nucleus occurs through the structures called nuclear 
pore complexes (NPCs) (Stoffler, Fahrenkrog et al. 1999; Allen, Cronshaw et al. 2000; 
Fahrenkrog and Aebi 2002; Fahrenkrog and Aebi 2003). The ions and small proteins 
(<40kDa) diffuse passively through the pore complexes, but the bigger proteins use 
soluble carrier proteins, called karyopherins (Radu, Blobel et al. 1995) to translocate 
actively through the nuclear envelope. The karyopherins who are involved in the import 
and export of the cargo into and out of the nucleus are termed importins (Gorlich, Prehn et 
al. 1994)and exportins (Stade, Ford et al. 1997), respectively. The Ran GTPase is the 
source of energy for this active transportation (Quimby and Dasso 2003). The Ran 
guanine nucleotide exchange factor (RanGEF) in the nucleus and the Ran GTPase 
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activating protein (Ran GAP) in the cytoplasm modulates the Ran nucleotide states 
(Bischoff and Ponstingl 1991; Becker, Melchior et al. 1995; Corbett, Koepp et al. 1995; 
Klebe, Prinz et al. 1995). By this regulatory effect Ran is asymmetrically distributed in the 
cell, with more RanGTP in the nucleus and more RanGDP in the cytoplasm (Kalab, Weis 
et al. 2002; Smith, Slepchenko et al. 2002) allowing a directional nuclear transportation. In 
the absence of RanGTP the import receptors bind the cargo in the cytoplasm and release 
the protein in the nucleus upon binding of the RanGTP to the complex. In the other way, 
the export receptors bind the protein in nucleus upon binding to RanGTP and release the 
cargo in the cytoplasm after the hydrolysis of GTP to GDP. The importin discriminates 
between its cargo containing the amino acid targeting sequences called nuclear 
localization signal (NLS), and the other cellular proteins. The NLS consists of either one 
(monopartite) or two (bipartite) stretches of basic amino acids (Kalderon, Richardson et al. 
1984; Dingwall and Laskey 1991; Robbins, Dilworth et al. 1991). In classical import 
pathway importin-α binds to the protein containing NLS in the cytoplasm and interacts 
then with importin-β (Gorlich, Kostka et al. 1995). Importin-β mediates the interaction of 
the complex to the nuclear pore. After nuclear translocation, RanGTP binds to and makes 
conformational changes in importin-β, leading to the release of importin-α-cargo complex 
(Lee, Matsuura et al. 2005). The binding of nucleoporin  Nup2 and the importin-α export 
receptor Cse1/RanGTP to an autoinhibitory region on importin-α results in the release of 
cargo from importin-α and export of importin-α to the cytoplasm (Kutay, Bischoff et al. 
1997; Hood and Silver 1998; Kobe 1999; Gilchrist, Mykytka et al. 2002; Harreman, Hodel 
et al. 2003; Matsuura, Lange et al. 2003; Matsuura and Stewart 2004; Matsuura and 
Stewart 2005) (Fig. 4.2).  
 Recently, a bipartite NLS in DLK has been identified in our group whose mutation 
prevents nuclear localization of DLK induced by pro-inflammatory cytokines (unpublished 
data). In this study the interaction of DLK NLS with nuclear importins was investigated 
(Fig. 3.8). The DLKwt protein interacted with importin-α, but neither with importin-β nor 
transportin. DLK NLS1 mutant showed very weak interaction to importin-α and no 
interaction to importin-β and transportin. DLK NLS2 mutant also showed no interaction to 
any of the importins. DLK-PP mutant, which is unable to homodimerize, also interacts to 
importin-α but neither to importin-β nor transportin, indicating that DLK does not need to 
be dimerized to interact with the importins. These data show that DLK use a classic NLS 










Figure 4. 2 The classical nuclear import cycle. In the cytoplasm the protein containing NLS 
binds to the Importin-α/importin-β heterodimer. Importin-α recognizes the NLS and importin-β 
interacts with the nuclear pore during translocation. When translocated into the nucleus, RanGTP 
binding causes a conformational change in importin-β resulting in the release of IBB (importin-β 
binding) region of the importin-α. Nucleoporin Nup2, export receptor Cse1, and an autoinhibitory 
domain work together to deliver and release the cargo in the nucleus. Finally, the export receptor 




  DLK in its inactive monomeric form is bound to JIP/IB-1 (JNK interacting 
protein/islet brain-1) and dissociates and homodimerizes upon phosphorylation of JIP/IB-1 
by JNK (Nihalani, Meyer et al. 2001; Nihalani, Wong et al. 2003). In addition, the previous 
work of our group showed that nuclear localization of DLK is needed to inhibit the CREB-
dependent gene transcription and to induce apoptosis in pancreatic β-cells (unpublished 
data). Thus, signals activating JNK such as pro-inflammatory cytokines may be amplified 
by the induction of DLK activity and nuclear localization. 
 In this study the nuclear localization of DLK driven by the pro-inflammatory 
cytokine TNFα was investigated in pancreatic β-cell line HIT (Fig. 3.9). TNFα triggers the 
nuclear localization of DLKwt in HIT cells, which proves the previous work of this group 
(unpublished data). TNFα also increases the nuclear localization of the DLK-PP mutant. 
The nuclear transport of the DLK-PP mutant under TNFα treatment is significantly 
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increased in comparison to non-treated cells, but is significantly less than DLKwt induced 
by TNFα. As previously reported, DLKwt inhibits the transcriptional activity of the CREB 
coactivator TORC (transducer of regulated CREB activity) while DLK-PP mutant showed 
no inhibitory effect (Phu do, Wallbach et al. 2011). These data suggest that, first a 
functional NLS is involved in the interaction of DLK protein with importin-α to initiate the 
nuclear transportation process, second the homodimerization of DLK is not necessary for 
the interaction with importin-α, but the disruption in DLK homodimerization changes its 




4.2 The effect of DLK on cell apoptosis and diabetes 
4.2.a. DLK and the activation of caspase-3 in HIT cells 
 Pro-inflammatory cytokines have been reported to induce apoptosis in βTC1 cells 
as well as rat and human pancreatic islet cells (Rabinovitch, Suarez-Pinzon et al. 1994; 
Iwahashi, Hanafusa et al. 1996; Delaney, Pavlovic et al. 1997) (chapter 1.2). In this study 
the role of pro-inflammatory cytokines in the apoptosis of pancreatic β-cell line HIT was 
investigated (Fig. 3.10). The cleavage/activation of caspase-3 was detected as a sign of 
the apoptosis. IL-1β and IFNγ alone showed a slightly increase in the activation of 
caspase-3 which was not significant compared to the non-treated cells. The combination 
of the IL-1β and IFNγ caused no increase in the cleavage of caspase-3, neither. Although 
the role of IL-1β alone or in combination with IFNγ in the induction of apoptosis in 
pancreatic islets has been reported (Eizirik and Mandrup-Poulsen 2001), such an effect 
could not be detected in HIT cells. TNFα treatment of the cells led to an increase in the 
activation of caspase-3, which had been hypothesized before (Fig. 1.4). The combination 
of TNFα and IFNγ resulted in a synergistic effect on the cleavage of caspase-3, debating 
the importance of the mixture of the pro-inflammatory cytokines in the induction of 
apoptosis in β-cells. 
 The intermediary role of DLK in TNFα and TNFα/IFNγ combination induced 
apoptosis was also investigated. The protein amount of DLK was down regulated using an 
anti-DLK RNAi (Fig. 3.11) and the cells were treated with different combination of the 
cytokines. The down regulation of DLK was less than 50% which was not enough to be 
taken part in the conclusion. In addition, the transfection method itself caused an increase 
in the activation of caspase-3, which might be just magnified by cytokines. Thus, another 
down regulation approach is needed to be more effective in the down regulation of DLK 
and less toxic in the case of induction of cell apoptosis. 
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4.2.b. Animal experimentation 
 Using DLK-heterozygote mice and their wild-type littermates of C57BL/6J strain, 
the probable participation of DLK in diet-induced diabetes was investigated. Several 
criteria were measured during the experiment, such as body weight, blood glucose and 
the glycated hemoglobin (HbA1c) (Fig. 3.12). The idea was to induce diabetes in two 
distinct ways of feeding. First, glucotoxicity induced diabetes by carbohydrate-rich diet 
(CRD) (Kluth, Mirhashemi et al. 2011), and second obesity dependent insulin resistance 
and pro-inflammatory cytokines destruction of β-cells through high-fat diet (HFD) (Sauter, 
Schulthess et al. 2008). No changes in body weight and blood glucose were observed in 
any of the genotypes under CRD and HFD compared to wild-type mice under normal diet 
(ND) (Fig. 3.12 A and B), meaning that overt diabetes has not been established. The 
plasma level of HbA1c was measured higher in heterozygote mice under HFD compared 
to ND (Fig. 3.12 D), but there was no difference between HbA1c level in wild-type and 
heterozygote under HFD (Fig. 3.12 E). These data suggest that this model using the DLK 
heterozygote mice of C57BL/6J strain is not a reliable model for concluding the role of 
DLK in diet-induced diabetes. A β-cell specific DLK knock-out mice model might be 
valuable for further investigation (see below). 
 
4.3 Generation of the conditional DLK knock-out mice 
DLK is an exception in MLK family, whose existence is pivotal for the survival, since the 
global knock-out of the both alleles of DLK in mice results in perinatal death (Brancho, 
Ventura et al. 2005; Hirai, Cui de et al. 2006; Bisson, Tremblay et al. 2008). Using a tissue 
specific knock-out mice model could be a good alternative to overcome this problem 
(Nagy 2000). In this model DLK is flanked by two loxP sites, the recognition site for Cre 
recombinase, in one sex, and in the other sex the Cre recombinase is expressed under 
the control of a promoter of interest, in this case rat insulin promoter to be specifically 
expressed in pancreatic β-cells (Cre mice are from Pedro-Herrera). The newborn mice 
resulted from the breeding of these two mice express flanked DLK in the whole body and 
the Cre recombinase only in pancreatic β-cells. The Cre recombinase cuts out the flanked 
DLK and results in mice which are knock-out for DLK in β-cells.   
 
4.3.a. Sequencing of genomic DLK in 129Sv mouse strain 
 Most of the gene-targeting experiments in mice are performed in 129Sv-derived 
embryonic stem (ES) cell lines, since these cell lines are more reliable at colonizing the 
germ line than the lines derived from other strains (van der Weyden, Adams et al. 2002). 
Since the genomic DLK sequence of 129Sv strain was not available in the scientific 
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resources the DNA extracted from 129Sv mouse was sequenced using primer nucleotides 
for DLK and compared to the sequence of DLK in C57BL/6J strain. Since no differences 
were observed in the sequenced area the available sequence of C57BL/6J strain can be 
used as well for the future analysis. 
  
4.3.b. Generation of targeting knock-out vector for DLK 
 The use of the Red genes encoded proteins of bacteriophage λ permits the 
efficient homologous recombination in E. coli (Zhang, Buchholz et al. 1998; Muyrers, 
Zhang et al. 1999; Datsenko and Wanner 2000; Murphy, Campellone et al. 2000; Yu, Ellis 
et al. 2000; Lee, Yu et al. 2001; Swaminathan, Ellis et al. 2001). Two Red genes are 
involved in the recombination process: exo, which encodes the 5’-3’ exonuclease (Exo) 
that makes 3’ single-strand DNA (ssDNA) overhang on the 5’ end of the linear double-
strand DNA (dsDNA), and bet, which encodes a pairing protein (Beta) that catalyzes the 
annealing of the 3’ ssDNA overhang generated by Exo to the complementary DNA strand 
on the vector. The activity of RecBCD exonuclease causes the unstability of the linear 
dsDNA in E. coli. The λ-encoded protein Gam participates in the successful recombination 
by inhibition of RecBCD (Stahl 1998; Poteete 2001). The recombination functions of the 
bacteriophage λ can be expressed by a plasmid (Zhang, Buchholz et al. 1998; Murphy, 
Campellone et al. 2000), or by the integration of a defective prophage into the E. coli 
genome (Yu, Ellis et al. 2000). When the prophage is integrated, E. coli expresses the 
recombination genes under the control of λ PL promoter. The promoter is under the control 
of temperature-sensitive λ cI857 repressor. At 32°C the repressor prevents the initiation of 
the expression of the proteins by promoter. Shifting the temperature to 42°C for 10-15 min 
removes the inhibition of promoter by the repressor and results in the very high level of 
recombination proteins’ expression. Based on these properties a protocol was established 
for generating the conditional knock-out vector (Liu, Jenkins et al. 2003)(chapter 3.4).  
 In this study the gap-repair protocol (Liu, Jenkins et al. 2003) was used to 
generate the conditional cko vector. A map was prepared for each step and the restriction 
digestion was performed according to the prepared map (Fig. 3.14 – Fig. 3.20). The 
accuracy of the recombination was proved via step by step sequencing. The excision of 
the neo cassette by the induction of Cre recombinase depicts the existence of the 
functional loxP sites (Fig. 3.19). The presence of a neo cassette allows the selection of 
the injected ES cells (Fig. 3.20). The exons 3-7 of DLK are flanked by loxP sites, which 
can be removed by Cre recombinase to generate a cell specific cko model in which DLK 
lacks the functional catalytic part of its protein.  
Summary 
 




Diabetes mellitus type 2 is the most increasing metabolic disease worldwide. The disease 
is recognized by the disability of endocrine pancreas to afford the high metabolic demand 
which has been raised due to insulin resistance followed by hyperglycemia. This failure 
might be addressed to both β-cell dysfunction and β-cell mass decline.  
 CRE- (cAMP response element) binding protein (CREB) is a transcriptional factor 
which plays an outstanding role in the survival and maintenance of β-cells. The mitogen 
activated protein kinase kinase kinase (MAPKKK) DLK (dual leucine zipper kinase) has 
been shown to inhibit the membrane depolarization-induced transcriptional activity of 
CREB and its coactivator CRTC. DLK phosphorylates and activates the stress activated 
protein kinase JNK (C-Jun N-terminal kinase). In this study the regulation of DLK by 
prediabetic signals was investigated in two ways. First the regulation of DLK kinase 
activity by prediabetic signals, and second the subcellular translocation of DLK induced by 
pro-inflammatory cytokines. Two point mutations were generated in the putative 
phosphorylation sites of DLK (Serin-298 and Serin-302) and the participation of these 
phosphorylation sites in the activity of DLK was investigated. Mutation in Serin-302 
residue abolished the inhibitory effect of DLK on CRE- and CBP-dependent gene 
transcription. The Serin-302 mutant was also unable to phosphorylate and activate JNK. 
These data suggest that Serin-302 residue is an important residue in the kinase activity of 
DLK. An antibody against DLK was produced which recognizes the phosphorylation of 
DLK specifically at Serin-302 residue. This antibody provides a valuable tool for 
investigating the activity of DLK. By use of this antibody we showed that pro-inflammatory 
cytokine TNFα alone and in combination with IFNγ activate DLK by phosphorylation of 
DLK at Serin-302 residue.  
 Previous study showed that pro-inflammatory cytokines TNFα and IL-1β induce 
nuclear localization of DLK in β-cell line HIT. In this study the interaction of DLK protein 
with nuclear receptors (α-importin, β-importin, and transportin) was investigated. The 
results showed that DLK interacts with α-importin but neither with β-importin nor with 
transportin. The mutation in DLK bipartite NLS destroyed the interaction with α-importin. 
These data show that DLK contains a functional bipartite NLS which interacts with the 
classic nuclear localization component α-importin which transports DLK into the nucleus. 
The mutation in leucine zipper sequence of DLK (DLK-PP) which prevents the 
homodimerization of DLK had no effect on the interaction of DLK with α-importin but 
decreased the nuclear localization induced by TNFα compared to DLKwt. This data 
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suggest that the homodimerization of DLK is not necessary for the interaction with nuclear 
receptor, but has an obvious effect on the stimulated nuclear translocation of the protein.  
 The role of DLK in the establishment of diet-induced diabetes was investigated 
using DLK heterozygote mice and their wild-type littermates. The data showed no 
establishment of diabetes in neither in wild-type nor in heterozygote mice. 
 DLK knock-out mice die perinatally. To investigate the role of DLK in function and 
survival of β-cells in an animal model, a targeting knock-out vector was designed and 
generated in this study. In this vector the exons 3 to 6 of DLK are flanked by two loxP 
sites which are recognized by Cre recombinase. The mice generated using this targeting 
vector, will be mated with the mice expressing Cre recombinase under the control of rat 
insulin promoter. The next generation express Cre recombinase in β-cells where it can cut 




These data show that DLK is regulated in two ways by prediabetic signals: 
1. TNFα induced the phosphorylation and thus the activation of DLK. 
2. TNFα and IL-β induce the nuclear translocation of DLK, whereby only nuclear DLK 
inhibits CREB-dependent gene transcription and induces β-cell apoptosis.  
Thus, it’s feasible that the β-cell specific inhibition of DLK provides a novel therapeutic 
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Zusammenfassung   
 Diabetes mellitus Typ 2 ist die metabolische Krankheit mit dem höchsten 
Prävalenzanstieg weltweit. Die Krankheit wird durch die Unfähigkeit des endokrinen 
Pankreas charakterisiert, adäquat auf metabolische Bedürfnisse zu reagieren. Die 
periphere Insulinresistenz, die aufgrund der Fehlfunktion des endokrinen Pankreas nicht 
ausreichend kompensiert werden kann, resultiert in erhöhten Blutzuckerspiegeln. Die 
Dysfunktion der β - Zellen und die Abnahme der β- Zelldichte können als Ursachen für die 
Fehlfunktion des endokrinen Pankreas angesehen werden.  
 CREB ( cAMP response element binding protein) ist ein Transkriptionsfaktor, der 
eine bedeutsame Rolle für die Aufrechterhaltung der β- Zellen spielt.  
Die mitogen-aktivierte protein kinase kinase kinase (MAPKKK) DLK (dual leucine zipper 
kinase) inhibiert die durch die Membrandepolarisation  induzierte transkriptionelle Aktivität 
von CREB und des Koaktivators CRTC.  DLK phosphoryliert und aktiviert die JNK ( C-Jun 
N-terminal kinase). In dieser Studie wurde die Regulation der DLK durch die 
prädiabetischen Signale auf zwei Wegen untersucht: Es wurden die Regulation der DLK 
Kinase Aktivität durch prädiabetische Signale und die subzelluläre Lokalisation der DLK 
untersucht. Die Bedeutung der Phosphorylierung von Serin-298 und Serin-302 in der 
katalytischen Domäne (der DLK) für die Kinaseaktivität wurde mittels Punktmutation in 
Alanin erzeugt. Mutation des Serin- 302 Rest hebt den inhibitorischen Effekt der DLK auf 
der CRE- und CBP- abhängigen Gentranskription auf. Zusätzlich war diese Mutante 
unfähig JNK zu phosphorylieren und damit zu aktivieren. Diese Daten weisen darauf hin, 
dass das Serin-302 eine entscheidende Rolle für die katalytische Aktivität der DLK spielt.  
 Es wurde ein Antikörper erzeugt, der spezifisch am Serin-302 phosphoryliertes 
DLK erkennt.  (Dieser Antikörper stellt ein nützliches Instrument zur Untersuchung der 
Aktivität der DLK dar.) Durch Verwendung des Antikörpers wurde gezeigt, dass das 
proinflammatorische Zytokin TNF-alpha alleine und in Kombination mit IFNγ aktiviert. Eine 
vorherige Studie in der β-Zell Linie HIT hatte gezeigt, dass die proinflammatorischen 
Zytokine TNFα und IL-1β eine nukleare Lokalisation der DLK induzieren. In dieser Studie 
wurde die Interaktion von DLK mit den Rezeptoren für den Kernimport (Importin-α, 
Importin-β und Transportin) untersucht. Die Ergebnisse zeigen, dass DLK mit Importin- α 
interagiert, aber weder mit Importin-β noch mit Transportin. Die Mutation in der 
zweigeteilten Kernerkennungssequenz (NLS) der DLK, hebt die Interaktion mit Importin-α 
auf. Diese Daten zeigen, dass DLK eine funktionelle zweigeteilte NLS besitzt, welche mit 
der klassischen nukleären Lokalisationskomponente Importin- α interagiert. Die Mutation 
in der Leuzin Zipper Sequenz der DLK (DLK-PP), die eine Homodimerization der DLK 
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verhindert, hat keinen Effekt auf die Interaktion der DLK mit dem Importin-α. Diese 
Mutation reduziert jedoch, verglichen mit der DLKwt, die TNFα stimulierte nukleare 
Lokalisation der DLK-PP. 
Diese Daten weisen darauf hin, dass die Homodimerization der DLK nicht für die 
Interaktion mit Importin-α erforderlich ist, aber Stimulus- induzierte nukleare Lokalisation 
von DLK verhindert.  
 Die Rolle der DLK bei der Etablierung der Diät-induzierten Diabetes wurde  durch 
heterozygote DLK Mäuse und ihren Wurfgeschwistern vom Wildtyp untersucht.  
Weder im Wildtyp Mäusen noch in DLK heterozygoten Mäusen konnte die Induktion von 
Diabetes durch Diät erreicht werden.  
 DLK Knock-out Mäuse sterben perinatal. Um die Rolle der DLK für Funktion und 
Überleben der β-Zellen im Tiermodell zu untersuchen, sollte ein β-zellspezifischer 
targeting Knock-out Vektor entworfen und generiert werden.  In diesem konditionellen 
DLK Knock-out Vektor sind die Exons 3 bis 6 der DLK von zwei loxP Sequenzen 
flankiert.Die mit dem targeting Vektor generierten Mäusen werden mit den Mäusen 
gepaart, welche unter der Kontrolle des Ratten Insulinpromoters, die Cre- Rekombinase 
expremieren. In den aus dieser Kreuzung  entstehenden Mäusen, schneidet die 
ausschließlich in den β- Zellen exprimierte Cre-Rekombinase die von den loxP-
Sequenzen flankierten DLK Exons 3 bis 6 aus, sodass die DLK spezifisch in den β-Zellen 




Diese Daten zeigen, dass die DLK auf zwei Wegen von den prädiabetischen Signalen 
reguliert wird:  
1) TNFα induziert die Phosphorylierung und folglich die Aktivierung der DLK. 
2) TNFα und IL- β induzieren die nukleare Translokation der DLK, wodurch die 
CREB-abhängige Gentranskription gehemmt und die β-Zell Apoptosis induziert 
wird. 
Die wenn möglich β-zellspezifische DLK stellt demnach ein neuartiges Ziel für die 
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